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Over the past decade, work from our laboratory has demonstrated the 
potential of targeted nanoformulated antiretroviral therapy (nanoART) to produce 
sustained high plasma and tissue drug concentrations for weeks following a 
single intramuscular (IM) administration that can suppress ongoing viral 
replication and mitigate dose associated viral resistance. While progress has 
occurred towards developing long-acting nanoformulations for protease and 
nonnucleoside reverse transcriptase (RT) inhibitors, development of 
nanoformulations of hydrophilic nucleoside RT inhibitor drugs have remained 
elusive. Abacavir (ABC); a hydrophilic molecule exhibited limited utilities to 
develop into long-acting nanoformulation platform. Furthermore, inefficient 
conversion of ABC to its biological active metabolites; carbovir triphosphate 
jeopardizes its therapeutic index.  Thus, improving bioavailability and the 
therapeutic index of the ABC is urgently needed. To this end, a phosphoramidate 
prodrug of ABC (PABC), and a myristoylated prdrug of ABC (MABC) was 
synthesized to improve the therapeutic index of its native hydrophilic counterpart.  
The notion of PABC synthesis was to increase intracellular nucleoside 5’-
O- triphosphate levels by bypassing rate-limiting monophosphorylation of the 
parent drug. We reasoned that long-acting PABC nanoformulations could 
improve ABC’s Pharmacokinetic (PK) and pharmacodynamics (PD). Herein, 
PABC was successfully synthesized and characterized by 1H-NMR and FTIR 
spectroscopy.  PABC was incorporated into a PLGA-lipid nanoformulation. In 
vitro and in vivo viral efficacy of PABC and PABC encased nanoformulation were 
evaluated in human monocytes derived macrophages (MDM) and Hu-PBL 
reconstituted NSG mice respectively. Concomitantly, a platform was constructed 
to convert the hydrophilic ABC into a hydrophobic derivative through 
esterification at 5’-OH position of ABC (MABC). MABC was loaded with high 
concentration into a polymer and decorated with appropriate targeting ligands for 
improvement in biodistribution, half-life and antiretroviral efficacy. Antiretroviral 
activity, uptake, retention and cellular trafficking of both the pro-drug and MABC 
encased in poloxamer nanoformulations were assessed in MDM. Drug PK was 
evaluated over 14 days for ABC and nanoformulated MABC after intramuscular 
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1.1 THE HUMAN IMMUNODEFICIENCY VIRUS (HIV): STRUCTURE AND LIFE 
CYCLE 
HIV is a class of viruses belongs to a group called retroviruses, and a 
subclass of retroviruses called as lentiviruses. A long hiatus between initial 
infection and the onset of AIDS occurs following HIV infection. Like all viruses, 
HIV survives and reproduces inside living cells, hijacking the host cell’s 
machinery to replicate.  HIV mainly infects the CD4+ T lymphocytes and to a 
lesser extent mononuclear phagocytes (MP; monocytes, macrophages, and 
dendritic cells) as these cells are also express cell surface CD4, a prerequisite 
for HIV to enter. Once infected HIV commandeers the cell, where cells eventually 
loses its function [1-3]. 
The genomics of HIV composed of ribonucleic acid (RNA) molecules, 
whereas the genes of most other organisms including humans are composed of 
deoxyribonucleic acid (DNA). However, once inside the cell, HIV like other 
retroviruses convert their RNA into DNA by using enzyme reverse transcriptase 
(RT), followed by its incorporation into the human cell’s genomes. To develop a 
delivery system for prevention of HIV, an understanding about the steps involved 
in HIV life cycle is crucial (Figure 1.1)[3-5]. There are multiple steps in the life 
cycle of HIV as explained below; 
1. Binding and Fusion: The first step in the HIV entry process (Figure 1.1) is the 
attachment of a viral particle to the CD4 receptor and a co-receptor (either CCR5 
or CXCR4) of the host cell. In particular, the gp120 of HIV bind to CD4 receptors, 
expressed on the surface of T lymphocytes, monocytes, macrophages and 
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dendritic cells. Binding to CD4 induce a conformational changes in the viral 
envelope that are necessary for membrane fusion and viral entry. The next step 
is the binding of gp120 to co-receptors CCR5 and CXCR4. After the first 
conformational change during the binding of gp120 to CD4 cell receptor, the viral 
gp120-gp41 glycoprotein complex undergoes further conformational changes, 
exposing the N-terminal domain of gp41 and allowing the fusion peptide 
sequence to insert into the cellular membrane of the host cell.  
2. Reverse Transcription: The fusion stage is followed by the reverse 
transcription and integration stages. The reverse transcriptase (RT) enzyme 
converts single-stranded HIV RNA into double-stranded HIV DNA through a 
process called reverse transcription, so it can be integrated into the host DNA. 
3. Integration: The new virus genetic material enters the nucleus of the CD4 cell 
and integrates itself into host genetic material with the help of integrase enzyme. 
Once the viral DNA has integrated into the host cell’s DNA, the host cell is 
infected for the remainder of its life. The integrated viral DNA is now called as a 
provirus. 
4. Transcription and Translation: The provirus DNA serves as a template for 
the creation of new viral RNA via a process known as transcription using the host 
cell enzymes. This results in the production of multiple copies of viral RNA. The 
newly formed viral RNA moves out of the infected cell’s nucleus. The viral RNA 
carries code for the synthesis of viral proteins and enzymes through the 
translation process. The code is translated into long chains of amino-acids 
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(polypeptide chains), which fold to produce structural proteins such as the viral 
envelope and enzymes (reverse transcriptase, integrase, and proteases). 
5. Assembly, Budding and Release: The protease enzymes cut the longer HIV 
proteins into individual proteins. When these come together with the virus genetic 
material, a new virus bud has been assembled. Budding is the final stage of the 
HIV virus life cycle. In this stage, the virus pushes itself out of the host cell, taking 
with it part of the membrane of the cell. This outer part covers the virus and 
contains all of the structures necessary to bind to a new CD4 cell and receptors 
and begin the process again. A single infected cell can release many new HIV 
particles which move on to infect other cells in various parts of the body, where 
the viral life cycle is repeated. The infected cells are eventually destroyed.  
1.2 THE HIV PANDEMIC 
In 1981, the CDC (USA) began investigation of rare opportunistic 
infections among a group of homosexual men. These patients were later 
confirmed to be severe immune deficient, and later their disease syndromes 
were coined as Acquired immune deficiency syndrome (AIDS) [6, 7]. In 1983, two 
independent groups in the United States and France simultaneously investigated 
the cause of these infections, and named Human T Lymphotropic Virus (HTLV-
III) and Lymphadenopathy Associated Virus (LAV) respectively [8-11]. In addition 
to HTLV-III and LAV, a third virus name AIDS-associated Retrovirus (ARV) were 
isolated from AIDS patient, later found to be the same virus,  and renamed as 
Human Immunodeficiency Virus, or HIV [12]. Since the epidemic began in the 
early 1980s, more than 75 million people have been infected and more than 30 
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million people have died of HIV-related infections. With 2.0 million new infections 
and 1.2 million deaths in 2014-2015, AIDS still remains the deadliest epidemic of 
our time. According to the recent report of the global AIDS epidemic, there are 
approximately 37 million people currently living with HIV/AIDS infections, 
corresponding to 0.8% of the total population of adults aged 15-49 years 
according to The Joint United Nations Programme on HIV and AIDS (UNAIDS) 
statistics[13, 14].   
1.3 CLINICAL MANIFESTATIONS 
HIV infection is distinguished into three phases; acute syndrome, clinical 
latency and clinical AIDS. Figure 1.2 shows a typical progression of the disease 
without antiretroviral treatment[15]. Note that CD4+ T cell counts drop rapidly 
during acute HIV disease, followed by a more gradual loss during clinical latency.  
During the early phase of infection, HIV can be detected followed by decline of 
plasma virus level to undetectable, and a phase of “latency” is ensured. The 
symptoms of early primary HIV illness, named as acute retroviral syndrome 
(ARS) can be seen within first 2-6 weeks. The symptoms are flu-like and non-
specific, and include fatigue, fever, lymphadenopathy, pharyngitis, anorexia, 
candidiasis, splenomegaly, hepatomegaly, oral lesions, and macular 
erythematous rashes, ulcers of genitourinary system, photophobia, and weight 
loss among others. The usual neurological symptoms observed are aseptic 
meningitis and headache. Approximately 70% of HIV infected the patients 
experienced ARS [16, 17].  
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The phase of acute infection is characterized by the active reproduction of 
virus and rapid declined in CD4+ T cells count, followed by inversion of CD4 to 
CD8 cells ratios. The numbers of HIV in peripheral circulation are in a range of 
105 to 106 HIV RNA copies/ ml. The acute HIV infection can be diagnosed by 
HIV-1 RNA testing, western blot assay, and by investigating HIV antigen and 
antibody using HIV enzyme-linked immunosorbent assay (ELISA).  
Followed by initial high viremia peaks, the level of HIV in the blood falls off 
to very low to non-detectable, and a phase of "latency" ensured. During the 
latency phase, few HIV symptoms are observed in patients, oral, skin, 
constitutional complications and an obvious persistent of lymphadenopathy are 
typical. Though HIV load is very low, a high turnover of CD4+ T cells and HIV 
virion production persist during this phase.  This stage of “latency” can be 
prolonged up to an average of 10 years without antiretroviral therapy (ART). 
Eventually, the viral load continues to increase and next stage of HIV prognosis 
termed ‘symptomatic HIV disease’ incept. 
In the late-stage of HIV infection, called Acquired immune deficiency 
syndrome (AIDS) viral load continues to increase.  CD4+ T lymphocyte cell count 
declined to a level less than 200-349 cells/μL in children older than 5 years. At 
this stage patient immune system is severely impaired, and patient succumbs to 
many opportunistic infections or malignancies like rare cancers (Kaposi's 
sarcoma) and other HIV infection manifestations (such as neuropathy) that 
eventually lead to death. HIV Patients with AIDS without on antiretroviral therapy 
(ART) usually cannot survive more than three years [17-21].  
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1.4 ANTIRETROVIRAL THERAPY (ART)  
Current regimen for ART includes combination of drugs that restrict HIV 
replication by targeting different stages of the viral life cycle. The use of a 
combination of antiretroviral drugs (ARVs) delay disease progression and 
diminish viral load for an extended period of time that led to profound decreases 
in morbidity and mortality rates in AIDS patient as well restricts HIV transmission 
from one person to another. A combination of protease inhibitor and nucleoside 
reverse transcriptase inhibitors (NRTIs) are the most used ART regimens. 
However, development of drug resistance, toxicity and complication associated 
with current regimen driving the development of novel antiviral agents that target 
HIV life cycle other than protease or reverse transcriptase. HIV entry inhibitors, 
viral integrase inhibitor that prevent integration of HIV DNA into the host DNA, 
virion maturation inhibitor etc. are currently potential emerging HIV targets for 
ART as shown in figure 1.3, The novel targets antiviral agents present new 
treatment options that are most likely to be fully effective against multi-drug 
resistance virus, and thus may act as synergistic to current other inhibitors[5]. 
  ART is now prescribed for all adults with HIV infection, with an initial 
prescription includes combination of two NRTIs; tenofovir disoproxil 
fumarate/emtricitabine or abacavir/lamivudine and a third single or boosted drug, 
which should be a boosted protease inhibitor or integrase strand transfer inhibitor  
or a nonnucleoside reverse transcriptase inhibitor. Table 1.1 present the general 




Table 1.1. Classification of Antiretroviral Drugs 
Classifications Ref. 
Category: Reverse Transcriptase (RT) Inhibitors 
MOA: RT Inhibitors block a process a process called reverse 
transcription, by inhibiting the activity of RT enzyme; transcription of 
single-stranded HIV RNA to double-stranded HIV DNA.  
Subcategory-1: Nucleoside/nucleotide RT inhibitors (NRTIs) 
MOA: NRTIs act by blocking RT enzyme. These drugs competitively to 
natural nucleoside analogs get incorporated into HIV DNA, leading to 
termination of DNA synthesis.  
Drugs: Abacavir, Lamivudine, Tenofovir, Adefovir, Emtricitabine, 
Zidovudine, Entecavir, Zalcitabine, Didanosine, Festinavir, Stavudine, 
Tenofovir disoproxil fumarate, Apricitabine, Tenofovir alafenamide 
fumarate. 
Subcategory-2: Non-nucleoside RT inhibitors (NNRTIs) 
MOA: NNRTIs inhibit the reverse transcription by binding to a pocket near 
the active site that leads to conformational change of the enzyme. 




Category: Protease Inhibitors  [25, 
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MOA: Inhibit virus-specific processing of viral Gag and Gag-Pol 
polyproteins in HIV infected cells by inhibiting viral protease. 
Drugs: Saquinavir, Lopinavir, Atazanavir, Darunavir, Ritonavir, Indinavir, 
Nelfinavir, Amprenavir, Fosamprenavir, Tipranavir 
26] 
Category: Integrase Inhibitors  
MOA: Inhibit the activity of HIV integrase, and thus block the integration of 
viral DNA into the DNA of the host cell. 
Drugs: Elvitegravir, Raltegravir, Dolutegravir. 
[27] 
Category: Fusion Inhibitors 
MOA: Inhibit the conformational changes required for viral membrane 
fusion with the cells, where it binds to the HIV-1 membrane glycoprotein. 
This inhibits HIV from entering a cell. 
Drugs: Sifuvirtide , Enfuvirtide. 
[28] 
Category: Entry Inhibitors 
MOA: Bind to gp120 receptors on the outer surface of the cell, and thus 
interfere with the virus ability to enter into host cell. 
Drugs: Maraviroc, Vicriviroc 
[28] 
Category: Maturation Inhibitors 
MOA: Maturation inhibitors blcok the last step in gag processing in which 





conversion of the polyprotein into the mature capsid protein. 
Consequentially, viral particles with a defective core is produced, and thus 
of non-infectious in nature. 
Drugs: Alpha interferon, Bevirimat, Vivecon. 
Category: Capsid Inhibitors  
MOA: Inhibitors of HIV-gag polypeptide assembly. Dismantles assembled 
HIV-1 capsid assembly tubes. 
Drugs: under investigation 
[31] 
Newer categories under development: 
LEDGF-based inhibitors, Budding inhibitors, RNaseH inhibitors, 




However, with the advent of current ART regimens, a profound decrease 
in morbidity and mortality rates in AIDS patient HIV is possible, but complete 
eradication is still a major challenge. The eradication of HIV is hampered by its 
ability to stay hidden in restricted anatomical sites and within infected blood cells 
to remain as a life-long infectious agent. It is much obvious that hidden virus into 
those anatomical reservoirs present a major challenge to combat HIV infection. 
Hence long-term use of ART regimens, which otherwise have adverse impacts, 
will continue at least in near future. 
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1.5 HIV RESERVOIR; A CHALLENGE IN HIV ERADICATION 
Combination antiretroviral therapy (cART) has substantially reduced the 
morbidity and mortality rate in HIV patient, but patient must  adhere to therapy for 
lifelong, and virus rapidly rebounds if therapy is discontinued [21, 33]. The major 
reason outlined the rebound of virus, and thus complete eradication is 
persistence of HIV reservoirs throughout the anatomical sites even patient is on 
ART [34, 35].  Therefore combat with latent virus in those reservoirs remains a 
formidable obstacle in complete eradication of HIV. This section focuses on 
recent advancement in understanding of where virus hides and established 
latency that would insight our efforts on designing formulation strategies that 
penetrate deep into these sites, and established a step toward the elimination of 
latent virus. The hide out of latent virus in a HIV patient is classified into two 
categories; 1) cellular reservoirs[36] and 2) anatomical reservoirs [37].  
1.5.1. Cellular Reservoir 
1.5.1.1. Memory T Cells 
The HIV infected resting memory CD4+ T cells and lymphoid tissue of HIV 
patients on cART was reported to be the source of persistence latency in late 
90’s. More recently, both transitional memory CD4+ T cells (CD45RA-CCR7-
CD27+) and central memory (CD45RA-CCR7+CD27+) have been reported as 
the major infected cells in HIV-infected patients receiving cART. Latency has also 
been identified in other T-cell subsets and other cell types are important to 
investigation, by which they may differ in mechanism of HIV persistence[36]. 
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1.5.1.2 Naive T Cells  
Persistence of latency in naive CD4+ T cells in HIV patients on cART has 
been reported, although the intensity of infection compared with memory CD4+ T 
cells is approximately 1–2 logs less. The concentration of HIV DNA in CD31+ 
naive CD4+ T cells (enriched for recent thymic emigrants), and CD31- naive 
CD4+ T cells (naïve cells that have undergone homeostatic proliferation) was 
found to be similar prior to and after cART. However, following cART the 
absolute number of infected naive CD4+ T cells was increased; suggesting that 
the reservoir of infected naive T cells may expand over time[36]. 
1.5.1.3 Hematopoietic Progenitor Cells 
 Recently, it has been evident that HIV can be persisting latently in CD34+ 
hematopoietic progenitor cells (HPCs).  Integrated HIV DNA was detected in 
CD34+ HPCs from 40% of patients on suppressive cART. Although, in vitro 
replication of HIV in HPCs showed to be cytotoxic, persistence of latent HIV 
could be established in these cells. Further detailed investigation are requires to 
understand how latency persist in these cells, whether these cells harbor 
infectious virus, and whether these cells could be a source of rebound virus when 
patients discontinued cART[36]. 
1.5.1.4 Astrocytes 
HIV infection of primary astrocytes and In vitro astrocyte cell lines results 
in integration but marginal virus replication that infers latent infection. Astrocytes 
isolated from the HIV infected patients exhibits the presence of integrated HIV 
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DNA, which linked to the HIV-associated dementia. However, such findings are 
from the viremic patients, further investigations on suppressive cART patient are 
require[36].  
1.5.1.5 Monocyte-Macrophages 
A number of factors lead to MP cell lineage of monocyte-macrophage as 
potential HIV-1 reservoirs. Monocytes circulate peripherally for up to three days 
before differentiate to macrophage.  Viral replication in to these cells is more 
persistent in nature which contributes to the low-level virus production lasting life-
span of cells. Limited expression of viral protein enables these cells to evade the 
immune system. However, the latency pool in monocytes-macrophages cells 
lineage is comparatively smaller than T-cells pools. Less than 1% of monocytes 
estimated to have HIV-1 proviral DNA, while about 50 in millions lymph nodes 
macrophages are found infected.  The lesser extent of infection is results of low 
CD4 surface expression which impair virus binding efficacy, but also to 
restrictions in nuclear import and reverse transcription leading to limited infection. 
The monocyte-macrophage HIV-1 reservoir reportedly exhibits resistance to 
protease inhibitors (PIs). The overexpression of P-glycoprotein transporters in 
these cells lineages suggested being the mechanism of resistance that limits the 
bioavailability of PIs[36].  
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1.5.2 Anatomical Reservoir 
1.5.2.1 Gastrointestinal Tract (GIT) 
The GIT is prominent reservoir for latent HIV infected cells in suppressive 
cART patient. The concentration of integrated DNA in GIT is reported to be five 
to ten times higher than in peripheral blood mononuclear cells. Within GIT, the 
distribution of HIV-DNA and RNA differ, with rectum having highest concentration 
of HIV DNA, and ileium with highest concentration of HIV RNA. A nonsignificant 
decrease in HIV RNA, suggesting ongoing HIV replication was observed in 
patient on suppressive cART [34, 37]. 
1.5.2.2 Lymphoid Tissue 
HIV infected CD+ T cells carrying integrated HIV DNA through the 
systemic and lymphatic circulation constitutes lymphoid tissue an important, 
although less studied reservoir in HIV patient receiving suppressive cART. 
Moreover, the follicular dendritic cells or other myeloid cells home to germinal 
center may provide a stable source of latent virus.  The interaction of dendritic 
cells to T-cells may contribute to the ongoing latency in resting T-cells [34, 37].  
1.5.2.3 Genitourinary Tract 
The presence of HIV RNA is detected in genital secretion in 54% of 
women and in semen in 8 to 10% of men receiving cART, indicating a reservoir 
in genital tract, although the source remains unclear. In the CNS, the limited 
bioavailability of cART to genitourinary tract makes it susceptible for ongoing 
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latency in these site. Moreover, the blood-testis barrier in male genitourinary 
tract, specifically restrict the entry of immune cells. In vitro study revealed that 
human testicular tissue can support HIV reproduction, but whether HIV- infected 
cells persist in these sites remain unclear[34, 37]. 
1.5.2.4 Central Nervous System (CNS) 
The CNS, with its long-lived unique cells, is identified as persistent 
reservoir for latent HIV in patient on cART. Since, the blood-brain barrier restrict 
the entry of cART and HIV-specific immune cells to the CNS, the CNS cells are 
more susceptible to HIV reservoir then peripheral cells and sites. Latently 
infected astrocytes and monocytes are potential source of HIV reservoir in brain. 
A low level of HIV RNA also has been detected in cerebrospinal fluid in about 
10% of patients receiving cART.  Further detailed investigation in HIV reservoir in 
CNS in patient on cART is desired [34, 37]. 
1.6 EFFORTS TOWARDS THE ERADICATION OF HIV-1 RESERVOIRS 
Although the introduction of highly active antiretroviral therapy (HAART) 
has considerably improve the quality of life and life-expectancy of HIV patients, 
complete eradication of virus, is so far, not possible. Several strategies have 
been proposed, and under development to eradicate HIV completely. 
Considerably, structured treatment interruption (SIT) and immune activation that 
may boost the intensification of HAART are of particular interest[38].  
SIT follows hypothesis that HIV specific immunity will be boosted by 
HAART interruption, through controlled exposure of virus over a predefined short 
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periods of time. It was expected that following several interruption, immune 
response will be adapted enough to control virus replication even in absence of 
HAART. However, despite intensive research and knowledge gained over SIT, 
the clinical outcome in terms of decreasing the intensity of lately infected cells 
population failed, in fact it has been associated with worsening the clinical 
outcome then of patients on HAART alone [39, 40].  
Immune activation therapy was designed to eradicate resting CD4+ T cells 
out of latency, and may be in combination with HAART boost the protection of 
uninfected cells. Several CD4+ T cells activating agents have been investigated 
in clinical studies including OKT-3, IL-2, and valproic acid. Didanosine and 
enfuvirtide in combination with Hydroxyurea was reported to boost HAART. 
However, in all case, evidence existed for rebound of virus upon discontinuation 
of therapy. Additionally, toxicity associated with HAART intensification limits the 
implementing, and thus clinical outcome[36]. 
The advancement of technology such as RNA interference that would 
silence the viral promoters within cells pool in HIV-1 reservoir would overcome 
the necessity for viral gene expression as well circumvent the toxicity associated 
with HAART intensification and immune cells activation[41]. Although these 
strategies towards HIV eradication are worth pursuit, their clinical efficacy is 
severely compromised by the specificity and delivery. The lack of specificity, in 
particular, delivery of antiviral agent to the virus hideout would obviously 
emphasize the need for the new drug delivery approaches to achieve HIV-1 
eradication. One of such interested drug delivery technology is utilizing body own 
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immunocytes. To this context, immunocytes, in particular mononuclear 
phagocytes (monocytes, macrophages, and dendritic cells) as drug delivery 
vehicle offer several advantages over conventional drug delivery [42].   
1.6.1 Macrophage-Mediated Drug Delivery: A Promising Approach In Latent 
Virus Eradication 
As discussed earlier (section 1.5.1.5), the long-lived macrophages make a 
perfect hideout for HIV for long period of time, thus constituting HIV reservoirs 
and posing a major challenge to complete virus eradication from HIV-infected 
patient. Mature HIV-1 can be stored within intracellular vesicles of macrophage 
for weeks (33). Evidences have suggested a key role of macrophages in the 
failure of the immune system to achieve HIV clearance within the acute and 
chronic phases of infection. Therefore, targeting drug delivery to 
monocytes/macrophages in particular, not only eliminates HIV but an opportunity 
to use the very mechanism(s) the virus uses to escape destruction[43]. 
Additionally, using macrophages as drug delivery vehicle offers several 
advantages over conventional drug administration regimens. These include 
predefined drug delivery to specific disease sites, in particular HIV anatomical 
hideouts; prolonged the biological half-life, thus PK of cART; controlled drug 
release; and minimize drug cytoxicity and immunogenicity. In addition, 
macrophage-mediated delivery can act as “Trojan horses” carrying hidden 
therapeutic pay-loads while transporting across formidable barriers; such as, the 
blood brain barriers [42].  
18 
 
Despite such advantages, clinical outcome for such system is jeopardized 
for several reasons. First, a poor drug loading into macrophage cells makes it 
inefficient delivery vehicle. Second, entrapped therapeutic agents may 
degrade/disintegrate within cellular compartments, lysosomal compartment in 
particular. Third, the macrophage should ensure loaded drug to stay within 
cellular vesicles till the cell reach to the predefined site of action or disease site, 
thus loaded payloads should not be released prematurely. Fourth, the cell 
carriers should transport to the disease site in therapeutically efficient quantities. 
In particular, transmigrating capability of macrophages should not be 
compromised during drug entrapment. Finally, the drug formulations must be 
safe enough to ensure all biological function of cells [42]. 
Many of these hurdle can be overcome by pre-packing the drug load/s into 
polymeric matrix that ensure a safest way to load high drug content that not only 
preserve the drug loads within cellular organelles but also sustain the release for 
an extended period of time [44].  Incorporation of drugs into protective polymeric 
nanoparticulate system is of particular interest by overcoming specified 
challenges.  
1.6.2 Design Consideration of Cell-Mediated Drug Delivery Construct 
The concept of cell-mediated drug delivery is very promising and under 
development. Specific considerations must be addressed ahead of time while 
constructing cell-carriers, for example, adequate drug loading capacity, controlled 
drug release at site of action, preservation of drug inside polymeric matrix and 
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endosomal vesicles, efficient homing of these drug carrying cells to site of 
interest and safety are some of important issues[42].  
1.6.2.1 Drug loading into the macrophages 
Nanocarriers commonly have a polymeric matrix core that permits drug 
entrapment, while outer polymeric layer define the nanocareers aqueous 
dispersion, systemic circulation time. The surface coating of these drug carriers 
have a notable impact on their interaction with macrophages that affects the 
cellular loading. In general, the macrophage uptake of charged nanoparticles are 
rapid and higher compared to neutral nanocarriers. Positively charged 
nanoparticles reported to accumulate in macrophages to a greater extent than 
negatively charged particles. The mechanism lies in the fact that positively-
charged nanocarriers likely to adsorb more on negatively-charged cell membrane 
of macrophage, derived by electrostatic attraction[45]. Moreover, the cell 
entrapment of these nanocarriers can be facilitated through engineering the outer 
surface using specific receptor targeting moiety that recognize specific receptors 
expressed on the cell surface, in particular, Fc, complement, mannose and folic 
acid receptors are among some of notable targeted receptors[46].  
The shape and size of nanocarriers have a significant impact upon cellular 
uptake. It has been reported that attachment of particles of different geometry to 
the macrophages surfaces are strongly dependent on shape and size. Particles 
that possess longest dimension, in the range of 2–3 µm exhibited superior 
attachment. The mechanism lie in the facts the macrophage evolved to engulf 
maximum number of bacteria, most of which exist in same size range. 
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Furthermore, the uptake of particles with the size about 1μm was significantly 
higher than particle with the size of about 500 nm[45].  Recently, the effects of 
shape on cellular uptake were investigated in alveolar rat macrophages using 
more than 20 shapes of   polystyrene-based particles. It has been revealed that 
shape of particles at the point of contact; where it attaches to macrophage play 
an important role in phagocytosis. For example, the attachment of sharper end of 
ellipse with macrophage would facilitate particles internalization within minutes. 
In contrast, macrophage attached to the particle on dull end side would limit 
phagocytosis [47].  
1.6.2.2 Drug preservation into the macrophages 
  The investigation of intracellular trafficking of the nanocarriers among 
other factors is of key important in defining the fate of drug encased nanocarriers 
once engulfed by macrophages. In particular, the drug loaded cargo need to by-
pass the lysosomes in order to avoid drug degradation within acidic cellular 
compartments [43]. In this context, the surface charge of nanocarriers is of key 
importance in defining the intracellular fate. For example, a diminished 
phagosomal acidification was observed with cationic polyamine coated 
nanoparticles compared with anionic protein coated nanoparticles. Therefore, the 
cationic nanoparticles sought to protect the drug from lysosomal degradation[48].  
In a recent study, it revealed that encapsulation of catalase into the positively 
charged block copolymers (PEI-PEG and PL-PEG) leads to improve stability of 
enzyme in macrophage. In contrast, the loading of enzyme into negatively 
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charged polyion complex resulted in degradation of enzyme within 
macrophages[49].  
The intracellular drug degradation can be circumvented by limiting the 
carriers being phagocytized, but attached to the cell surface. The “back-pack” 
attached to the monocytes/macrophages surface would be hitchhiked to the site 
of interest that also improve systemic circulation while preserved encased drug 
activity. The avidin coated nanoparticles reported to attach with biotinylated 
plasma membrane through the avidin-biotin complex to constitute stable “back 
pack”. However, further studies needed to investigate the drug carrying capacity 
and immunogenicity of such polymeric “back pack” [50]. 
1.6.2.3 Drug release from the macrophages 
Mechanism underlying the unloading of these nanocarriers at the site of 
action remains an active area of investigation. However, a desired controlled 
release of cargo has modulated the dose and duration of exposure. To such end, 
cellular response to various physical or chemical stimuli can be utilized to trigger 
the release. Macrophages, along with mononuclear phagocytic cells, are known 
to produce and store the various compound within endosomal vesicle, followed 
by their released via exocytosis at disease site. A similar mechanism can be 
anticipated for the release of drug and /or drug -loaded carriers, when serve as 
drug delivery vehicles. However, further detail investigations are needed to 
understand the exact mechanism [42].  The release of drug can be modulated 
using external stimuli. For example, by modulating the intracellular concentration 
of Ca2+ the drug release can be triggered [51].  Furthermore, the use of mild 
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hypothermia was reported to control the release of drug-loaded liposomes from 
macrophages in tumor vicinity[52].  
1.6.2.4 Drug depot  
For cell-mediated drug delivery the numbers of drug carrying cells reach 
the site of action of key importance. For example, in case of CNS disorder the 
efficacy of cell-carriers is determined by the ability to cross the blood brain barrier 
(BBB) to elicit therapeutic end point.  For most of cells-carriers the driving force 
to the disease site is chemotaxis; a process where most of MP migrate to the 
disease site following chemogradient. In many CNS disorder, such as 
Parkinson’s and Alzheimer’s disease, meningitis, encephalitis, prion disease and 
HIV-associated neurocognitive disorders (HAND) exhibited similar inflammatory 
components that recruit MP extensively to the disease periphery. Additionally, 
neural stem cells (NSCs) were also reported as drug delivery vehicle for gene 
delivery in brain. Indeed, these cells transmigrate more efficiently to the disease 
site including neoplastic brain lesions and ischemic lesions. However, the 
mechanism to which they transmigrate to the disease area is not clear yet, 
although NSCs reported to express a wide variety of receptors that may render 
them to respond to many chemotactic signals. In particular, activate microglia 
drive NSCs influx to the brain. Therefore, cell-mediated strategies can be 
employed to deliver wide range of neurotropic factors that otherwise restricted 
due to brain formidable barriers i.e. BBB [42].   
In context of cell-mediated drug delivery of anticancer agent, MP are 
known to migrate in large number at tumor site, in particular, vascular and 
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hypoxic site, for example in prostate and breast carcinomas. Malignant tumors 
have lots more hypoxia due to their unorganized vasculature. The hypoxia driven 
cytokines from tumors cells and other physiological stress are the chemotactic 
markers that accumulate monocytes and macrophages in tumor vicinity that 
facilitate anticancer drug delivery to the cancerous region using these cells as 
delivery vehicle[53]. The advantages of cell-carriers in anticancer drug deliver are 
to avoid unwanted drug distribution and minimize off-target drug toxicity.  
Cells-carriers can be deployed to the disease site by incorporating 
magnetic nanoparticles into the therapeutic cargo and fed to the cells carriers 
following accumulation at disease site with the aid of external applied magnetic 
field. Intravenous injections of RGD-coated magnetic liposomes in albino rats 
with brain inflammation exhibited 10-folds brain accumulation under the magnetic 
guidance compared to non-magnetic nanoparticles. RGD peptide facilitated 
selective binding of these nanoparticles to the surface of 
monocytes/macrophages that expressed integrin receptors on cellular surface 
[54].    
1.6.2.5 Safety of cell-mediated drug delivery 
One has to be cautious about safety concern while designing cell-carriers 
constructs. In particular, the MP migrates to the disease site is usually 
accomplished by release of reactive oxygen species (ROS) that cause cell 
damage. To this context, many of CNS therapeutic strategies are designed to 
limit the monocytes/macrophages infiltration the brain. Therefore, circumventing 
cytotoxicities for cell-based drug delivery construct is a prerequisite for 
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formulation development of cell-mediated drug delivery system.  Nevertheless, in 
particular, brain delivery of macrophage-mediated nanoformulated catalase 
showed no cytotoxic effects [42]. Furthered detailed investigations are required to 
preclude any pitfall of cell-mediated drug delivery for acute and chronic 
applications.  
1.7 DESIGN CONSIDERATION OF NANOMEDICINE FOR EFFICIENT CELL-
CARRIERS 
One has to be very cautious while choosing right drug packed particulate 
while constructing cells-based drug carriers in order to maximize the therapeutic 
outcome with least side effect, or that does not have any impact on the integrity 
of cellular carriers. The designs of nanocareers need to be optimized in terms of 
particles size, shape, and surface chemistry to maximize the cellular uptake, and 
thus efficacy of loaded drug/s. all these characteristics are critical for clinical 
translation of these carrier system. 
1.7.1 Shape, size and surface charge of nanocarriers 
Nanoparticles shape and size are the critical parameter which affects the 
rate of macrophage uptake. Champion et al revealed that particles of size 2–3 
μm in diameter exhibited maximal macrophage uptake via phagocytosis and 
attachment. However, the rate of internalizations is independent of by particle 
size. The particle size dependence of phagocytosis is governed primarily from 
the attachment of particles to the surface of macrophage. Furthermore, the 
macrophage membrane ruffles is hypothesized to be the reason of   maximal 
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attachment of 2–3 μm microspheres, the elimination of which through osmotic 
swelling nearly diminished the peculiar size-dependence of phagocytosis. In 
particular, particles of size around ~2 µm are phagocytosed more rapidly than 
smaller or larger particles. Alternately, particles with hydrophobic surface are 
uptake more rapidly via phagocytosis than particles with hydrophilic surfaces. 
Consequentially, particle surface are modified by neutral hydrophilic polymers 
such as polyethylene glycol (PEG) to modulate the phagocytosis. Nanoparticle 
synthesis methods and process should be choose and modulate based upon the 
targeted size. The aspects like drug/polymer ratio, polymer/surfactant 
concentration, solvent type and stirring/homogenization rate are some of few 
important considerations [47, 55, 56]. 
The impact of particles shape on phagocytosis is recently beginning to be 
investigated. Champion and Mitragotri [56] recently revealed from their finding 
that the shape of particles has crucial impact on phagocytosis by macrophages; 
the oblate ellipsoid particles are more rapidly phagocytosed than particles with 
spheres or prolate ellipsoid shapes. The shape of particles triggered 
phagocytosis via cell attachment and internalization. The shape-dependency of 
phagocytosis is potentially linked to the actin remodeling by the macrophage 
cytoskeleton, since phagocytosis is an actin–linked process. Since actin 
remodeling is energy deriving process, in theory, the shape that require more 
energy for actin remodeling, should be internalized slower. Therefore, the fact 
that oblate ellipsoids are phagocytosed more rapidly and efficiently than prolate 
ellipsoids is due to their lower aspect ratio and actin remodeling which require 
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less energy for internalization. Furthermore, it has been reported that cylindrical 
rods shape particles are advantageous in terms of macrophages uptake. The 
mechanism reflects the preference of macrophages for engulfment of most 
bacteria that have a rod shaped geometry in nature. 
Surface charge of the nanoparticles has exhibited to be a major 
determinant of cellular uptake, which highly depends upon cell types. For 
macrophage uptake, the positively charged particles are more prone to 
sequestration by macrophages in the spleen, lungs and liver. In contrast, neutral 
and slightly negatively charged nanoparticles are of least preference for 
macrophage uptake [45]. 
1.7.2 Drug Loading and Encapsulation Efficiency  
Drug loading or encapsulation efficiency of a formulation is a measure of 
intensity by which drug retain within polymeric matrix.  In general a high drug 
loading or encapsulation is required that negate the need of higher dose of 
nanoparticles which otherwise administered a large volume of excipient/s. Drug 
loading measures the mass of the drug entrapped within a polymeric matrix 
during nanoparticle preparation compared to the mass of excipients. It is 
calculated from the following equation; 
 Drug loading (%) = (mass of drug in nanoformulation)/ (total mass of 
nanoformulation) X 100 
Whereas, encapsulation efficiency of a formulation measure the ratio of 
drug encapsulated in nanoformulations verses total drug added. It is important to 
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purify the nanoparticles to get rid of unencapsulated drug and surface adsorbed 
drug before calculating the drug encapsulation and loading parameters. Drug 
loading is dependent on the process of formulation, nature of excipients, and 
type of nanoparticle itself (polymeric nanoparticles, solid lipid nanoparticles, 
dendrimers, etc.). For drug loading analysis, freeze dried powder of formulation is 
disrupted in a solvent to release the encapsulated drug, whereas encapsulation 
efficiency is measure by analyzing remaining drug in purified supernatant. A 
higher drug loading indicates lesser amount of non-active excipients and small 
volume of injections needed to achieve a bioequivalent drug dose [57]. 
1.7.3 Drug Release 
The rate and extent of drug release from polymeric matrix is very crucial to 
determine therapeutic efficacy of formulation. Drug release can be coined as the 
opposite of drug loading. In particular, drug release is a mass transfer process 
from the polymeric matrix to the surrounding release media. The release of 
encased drug in a media is governed by many factors including interaction of 
drug with excipients, chemical characteristics   of drug and polymer and nature of 
release media itself.   
The rate of drug release from a matrix can be calculated using Fick’s law of 
diffusion. In facts, Ficks’s law of diffusion is a mathematical simplification of a 
complex process driven by   complex physicochemical parameters influencing 
the drug release[58].  
28 
 
1.8 ANIMAL MODELS OF HIV 
Since HIV only infects human, it is a major hurdle in choosing a relevant 
animal model.  HIV is specific to human immune cells, which are bound to 
specific genetic factors critical for their life cycle. These include binding of HIV to 
immune cells via CD4 receptor, and co-receptors CCR5 and CXCR4. Attempts 
were made to fabricate those receptors over murine cell, but yet not succeed, 
which in part, is due to absence of many human specific factors. Furthermore, 
attempts were made to generate a chimeric strain of HIV by modifying HIV itself; 
SHIV reported to replicate in monkey. Although, chimeric strain facilitates to 
immune responses to vaccine construct, but differ in response that was produced 
with HIV infection.  Limited successes were seen with some other notable 
approach such as HIV encoded gene expression[59]. Therefore, to this end, 
there is a prime need to generate relevant animal model to study HIV-1 infection. 
Humanized mouse model, in this context studies as reasonable alternative.  
Chronic humanized mouse model is accomplished by expression of 
human transgene or transplanting human tissue into immune deficient mice. 
Since these mice are immune deficient [severe combined immunodeficiency 
(SCID)] that involve mutation in prkdc gene that spontaneously deplete B and T 
cells population, the host-rejection of graft is lacking. 
1.8.1 Human Peripheral Blood Lymphocytes (Hu-PBL) Reconstituted Mice 
Humanized mouse model created by knock down of Prkdc gene 
successfully exhibited immunodeficiency but with leaky production of T and B 
cell, and high level of natural killer (NK) cells. Additionally, the mutation in IL-2 
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(gamma chain receptor) renders the lack of IL-2 signaling in B and T cells that 
leads to more efficient xenograft. Furthermore, the knock down of recombinase 
activating genes 1 or 2 (Rag1/Rag2) produce xenografts with no leaky B and T 
cells. Furthermore, the mutation of non-obese diabetic (NOD) gene leads to drop 
down of NK cells production. Therefore, combining all mutation produce a much 
stable engraftment generally referred to as NOD/scidIL- 2Rgc null (NSG) 
mice[60]. 
The Hu-PBL reconstituted mouse is prepared by injecting human PBL 
intraperitoneally into NSG mice that render them susceptible to HIV infection. 
The Hu-PBL reconstituted mouse showed upregulation of Human leukocyte 
antigen- DR (HLA-DR) and CCR5 that leads to production of xeno-reactive T 
cells. However, due to the graft-versus-host reactions, these mice are 
susceptible to die. Moreover, the mouse model is restricted by lack of 
hematopoiesis and graft-versus-host response, which limit their usefulness for 
chronic infection. However, the ease of preparation and availability make them 
alluring for acute infection studies [61].  
1.9. SIGNIFICANCE OF THE PROJECT  
ABC is an antiretroviral drug used for preventing and treating HIV/AIDS.  It 
is a nucleoside analog acting as a chain terminator for the reverse transcriptase 
inhibitor and called a NRTI as a consequence.  It is under the trade name 
Ziagen.  Importantly viral strains that are resistance of zidovudine or lamivudine 
(3TC) can be sensitive to ABC.  It has a variety of secondary toxicities that 
include nausea, headache, fatigue, vomiting, hypersensitivity reaction, diarrhea, 
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fever/chills, depression, rash, anxiety, URI, ALT, AST elevated, 
hypertriglyceridemia, and lipodystrophy.  An important hypersensitivity syndrome 
is associated with its use.  This reaction is strongly associated with a specific 
allele at the human leukocyte antigen B locus namely HLA-B*57:01.  
Nonetheless, it possesses the unique property of strong penetrance of the blood-
brain barrier (BBB) and as such would be of significant use to restrict viral 
infection within the brain and spinal cord and used concurrently with agents 
designed to eradicate viral infection[62].  Thus, it is of significant interest to our 
group of investigators. 
The study will be conducted in four phases.  The first will explore the 
manufacturing capabilities of the novel nanoformulation. NMR tests will confirm 
the formation of the pro-drug.  The second phase will be in preparing the pro-
drug for polymer encasement with appropriate decoration with a targeting ligand 
or ligands. In the second phase size, charge, morphology and polydispersity will 
be measured.  In the third stage, stability will be tested by taking the formulation 
from storage at 4 °C and 25 °C every 10 days for 60 days and measuring the 
same parameters developed in stage two.   The fourth stage will test its 
antiretroviral responses by allowing monocyte derived macrophages to be 
infected following 1, 5, 10 and 15 day initial exposure to the variant 
nanoformulation manufactured at a spectrum of drug concentration. Toxicity 




The studies will be focused on developing folic acid (FA) targeted, long-
acting parenteral nanoformulations of Abacavir prodrugs. The overarching goals 
would be to extend the pharmacokinetic (PK) and pharmacodynamics (PD) 
profile of native hydrophilic counterpart i.e. ABC, specifically targeting them to 
macrophage receptors using folic acid ligand coating. 
Long-acting parenteral nanoformulations circumvents several pitfalls of 
conventional oral drug delivery like treatment off-target toxicity, poor PK and 
biodistribution, drug-drug interactions and limited therapeutic end point. The long-
acting nanoformulations results in targeted drug delivery to viral reservoir sites 
with uniformity in PK parameters. Several potent antiretroviral agents were 
discontinued due to their poor PK and undesirable physicochemical 
characteristics such as poor dissolution, instability in GIT fluids etc.   Formulating 
such drugs as long-acting nanoformulation can circumvent such issues and 
probability of getting these drugs back to market is high. Because in 
nanoformulation encased drug is protected within polymeric matrix and inside 
stable intracellular compartments, the probability of drug-drug interaction with 
other drug and adverse effects will be considerably reduced[63].  
The other important implication of long-acting nanoformulations is by 
reducing the dosing frequency and overall dose that lead to improved patient 
compliance by decreasing treatment associated anxiety in patients. Furthermore, 
long-action nanoformulations can ameliorate viral resistance and patient 
adherence against ART[64].  Specially, this will be very beneficial to the patients 
with concomitant substance abuse, which are usually non-adherent to treatment 
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regimens. Therefore, such patient’s population is usually not treated with ART 
because of higher risk of transmission of resistant species of HIV-1 to uninfected 
individuals.  
In future, with long-acting nanoformulations platforms using robust 
manufacturing procedures, once six months or even less frequent dosing 
regimen can be achieved. Such dosing regimen holds promising in HIV 
eradication as of their ability to reach deep penetrating in to HIV reservoir, which 
otherwise formidable to conventional dosing regimen. Even though complete 
eradication is not possible, the diminished of viral rebound can be feasible with 
such dosing regimen.  Additionally, it is possible to administered long-action 
nanoformulations in to individual living in high-risk population as pre-exposure 
prophylaxis, or PrEP.  
Long-acting nanoformulations by constructing macrophage-mediated 
delivery system even with frequent dosing could drastically improve the 
therapeutic outcome by penetrating deeper into anatomical HIV-1 reservoir.  The 
ability of long-acting NanoART to penetrate deeper into these HIV reservoir 
tissue would considerably suppress viral production manes it provide a mean for 
immune system to better handle co-morbid conditions.  This would turn very 
beneficial for patient with co-morbid conditions living in resources limited setting. 
Furthermore, the ability of long-acting NanoART to circumvent drug resistance 
and decrease drug associated toxicities present a means to reduce the cost 































































Figure 1.5. Macrophage particle uptake in different organs including the 
lungs, liver, spleen and kidneys are dictated by size, shape and surface 
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 HYPOTHESIS AND SPECIFICS AIMS 
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2.1. HYPOTHESES  
We proposed that macrophage-targeted nanoformulations of Abacavir prodrugs 
will facilitates uptake, retention and antiretroviral efficacy in cultured monocyte-
derived macrophages (MDM), and will improve pharmacokinetics, biodistribution, 
and pharmacodynamics efficacy in murine models of HIV-1. 
Our lab has pioneered in developing long-acting NanoART that may 
facilitate patient compliance by permitting once weekly or bi-weekly dosing 
regimen. It has been reported that macrophage are the first cells pools that 
encounter HIV first, and play a critical role through the HIV prognosis. Also, the 
natural ability of macrophage to reside at the site of virus hideout i.e. lymph-
nodes, spleen, liver etc. further aid the beneficial of homing the drug depot at the 
site of action. Thus we posit that macrophage-targeted drug delivery can improve 
the PK profile and render the biodistribution at right place, thus improve 
therapeutic efficacy while reducing off-target toxicity of drug. We tested this 
hypothesis in following two parts of the projects;  
Project 1: A phosphoramidate prodrug of abacavir (P-ABC), was synthesized to 
improve the biological activities of the parent nucleoside. The idea is to increase 
intracellular nucleoside 5’-O-triphosphate levels by bypassing rate-limiting 
monophosphorylation. This would lead to decreased activity of the virus encoded 
reverse transcriptase. A prodrug could readily incorporate into poly(lactic-co-
glycolic acid) (PLGA) nanoparticles and as a consequence affect the efficacy of 
long-acting P-ABC nanoformulations as measured by pharmacokinetics and 
pharmacodynamics (PK and PD) tests 
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Project 2: A myristic acid derived hydrophobic prodrug of ABC (M-ABC) was 
synthesized. M-ABC would then be loaded at high concentrations into a 
decorated polymer coating with targeting ligands aimed to improve 
biodistribution, drug half-life and antiretroviral efficacy in viral target CD4+ T cells 
and monocyte-macrophages. To this end we incorporated M-ABC into poloxamer 
(P407) then decorated the particle with folic acid.  These modifications positively 
affect macrophage uptake and antiretroviral efficacy 
For both projects, hypothesis will be tested under following specifics aims; 
Specific Aim 1: Synthesis, Characterization and Nanoformulation of 
Abacavir Prodrugs 
The objective was to synthesize phosphoramidate prodrug (PABC) 
(project 1), and myristoylated prodrugs (MABC) (project 2) of Abacavir. The 
prodrugs were characterized using 1H-NMR, FTIR and mass spectroscopy. 
Antiretroviral activity as measured by the EC50 was compared amongst the 
PABC, M-ABC and frees ABC in MDM. The prodrugs were nanoformulated using 
PLGA (project 1) and poloxamers (P407) or folate conjugate poloxamers (FA-
P407) (project 2) as excipients.  Nanoformulated prodrugs were characterized for 
physicochemical parameters such as; size, size distribution (PDI), surface 
charge, drug loading and stability.   
These parameters are of key importance in determining their cell 
cytotoxicity and cell interactions. The folate coating integrity determines the 
macrophage target ability, and thus antiretroviral efficacy and in vivo PK/PD fate 
of nanoformulated prodrugs.   
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Specific Aim 2: In Vitro Characterization of Nanoformulated Prodrugs in 
MDM 
The objectives of this aim were to (a) determine the uptake, retention and 
antiretroviral efficacy of nanoformulated prodrugs in MDM; (b) study the 
intercellular trafficking of nanoformulated prodrugs in MDM; and (c) to assess the 
cytotoxicity of nanoformulated prodrugs in MDM. The overarching goal of this aim 
was to develop superior nanoformulation for animal testing that can be 
extrapolated for human testing in near future.  
Specific aim 3: PK and PD Characterization of Nanoformulated ABC 
Prodrugs in Wild Type Mice and in Murine Models of HIV-1. 
Optimized nanoformulations for both prodrugs from aims 1 and 2 were 
evaluated in murine models of HIV/AIDS.  With optimized formulations (a) the PK 
testing in Balb/cJ mice were assessed to determine drug levels in plasma and 
tissue, and (b) correlated to antiretroviral efficacy in HIV infected NOD/scid-gcnull 
(hu-PBL-NSG) mice.  The formulations were administered parenterally to Balb/cJ 




























Abacavir (ABC) is a nucleoside reverse transcriptase inhibitor (NRTI) that 
is used in combination with non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), protease inhibitors (PIs) and integrase strand transfer inhibitors 
(InSTIs), as components of a first line treatment regimen for human 
immunodeficiency virus (HIV) infection by the National AIDS Control 
Organization [1, 2]. Notably, the viral strains that are resistant to zidovudine or 
lamivudine are sensitive to ABC [3]. However, ABC is associated with a dose 
dependent hypersensitivity response linked  to the HLA-B*5701 allele that can be 
fatal if therapy is not discontinued [4]. Inefficient phosphorylation of ABC into its 
active metabolite carbovir-5’-triphosphate (CBV-TP) compromises the overall 
efficacy resulting in required high therapeutic doses of ABC [5]. Metabolic studies 
of ABC revealed that adenosine phosphotransferase predominantly metabolizes 
ABC to ABC-monophosphate (ABC-MP), which is subsequently converted to 
carbovir-5-monophosphate (CBV-MP) by cytosolic deaminase. CBV-MP is then 
anabolized to CBV-TP by cellular kinases. CBV-TP is the biologically active 
metabolite that terminates DNA synthesis by inhibiting the virus-encoded reverse 
transcriptase (RT) [5]. However, ABC has been shown to be a poor substrate for 
adenosine phosphotransferase, resulting in inefficient conversion to the 
monophosphate derivative (ABC-MP) [6]. Monophosphorylation is, thus, the rate-
limiting step in determining the efficacy of ABC. In fact, the efficacy of the 
majority of nucleoside analogs, not only ABC, is compromised by the inefficient 
first-step monophosphorylation. Stavudine (d4T), zalcitabine, didanosine and 
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gemcitabine are examples where relatively poor monophosphorylation severely 
compromises the efficacy of the drug [7-9].   
To overcome such challenges, several attempts have been made to 
deliver phosphorylated nucleoside analogs directly into the infected target cells 
[10]. ProTide technology that generates phosphorylated nucleoside analogs 
(pronucleotides) is widely utilized to bypass the poor phosphorylation step of 
nucleosides. Pronucleotides are phosphorylated prodrugs in which a masked 
phosphate moiety is covalently linked to the hydroxyl group of the nucleosides. 
Masking of the phosphate moiety through a benzyl ring at one end, and a L-
alanine methyl ester at the other end improves the hydrophobic nature of these 
compounds, and thus facilitate cellular entry of the phosphorylated prodrug [11]. 
The concept of ProTide technology was first introduced for cancer treatment in 
1982 with the synthesis of the pronucleotide prodrug, cytosine arabinoside 5ʹ-
monophosphate [12]. The clinical efficacy of the antiviral pronucleotides of 
adefovir dipivoxil and tenofovir disoproxil was confirmed and the drugs approved 
by the FDA [13-15]. Several other antiviral and anticancer pronucleotide prodrugs 
are under clinical development [10].  It is important to know whether a 
pronucleotide prodrug of ABC can result in improvement of antiretroviral activity. 
McGuigan et al. [16] reported the first application of ProTide technology to ABC 
and observed that the anti-viral potency of the ABC pronucleotide was improved 
significantly (70-fold) in human T4 lymphocyte CEM cells.  
Lack of sustained and effective viral suppression rests in the inability of 
drugs to specifically target HIV viral reservoirs [17]  which include lymph nodes, 
54 
 
gut-associated lymphoid tissue (GALT), spleen, central nervous system (CNS) 
and central memory lymphocytes and myeloid cells contained within the 
lymphoreticular tissues [18-20]. Lack of achievement of optimal drug levels in 
these reservoir sites can lead to the establishment and perpetuation of viral 
sanctuaries, and thus treatment failure [21, 22]. We posit that development of an 
effective delivery scheme for nucleoside prodrugs to extend plasma drug half-life 
and facilitate drug delivery into HIV anatomical reservoirs would increase their 
therapeutic utility. 
In this study, a pronucleotide prodrug of ABC (PABC) was synthesized and 
encapsulated into a lipid-PLGA based nanocarrier. The mixed lipid outer covering 
of the PLGA core enabled the sustained release of drug cargo over an extended 
period of time. Antiretroviral efficacy of PABC and nanoformulated PABC were 
evaluated in human macrophages and a humanized mouse model of HIV 
infection. 
3.2. MATERIALS AND METHODS 
3.2.1. Chemicals 
Abacavir (ABC) sulfate, phenyl dichlorophosphate, L-alanine methyl ester 
hydrochloride salt and poly (D, L-lactide-co-glycolide; lactide:glycolide (75:25), 
mol wt 66,000-107,000) (PLGA) were purchased from Sigma-Aldrich (St. Louis, 
MO). ABC sulfate was titrated with sodium bicarbonate to convert it into free-
base. DSPE-mPEG2k (distearoyl-phosphatidylethanolamine-methyl-polyethylene 
glycol conjugate-2000), DSPC (1, 2-distearoyl-sn-glycero-3-phosphocholine) and 
DSPG (1, 2-distearoyl-sn-glycero-3-phosphoglycerol) were purchased from 
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CordenPharama (Cambridge, MA). Phosphate-buffered saline (PBS), Optima 
grade water and high performance liquid chromatography (HPLC) grade 
acetonitrile, methanol, dichloromethane (DCM) and tetrahydrofuran (THF) were 
purchased from Fisher Scientific (Fair Lawn, NJ). Rabbit anti-human antibodies 
to Rab5, Rab7, Rab11, and Rab14, and AlexaFluor 488 conjugated goat anti-
rabbit IgG were purchased from Santa Cruz Biotechnology (Dallas, TX). A dry 
argon atmosphere was practiced to perform the chemical reactions. Flash silica 
gels (32-63 μm) from Dynamic Adsorbents Inc. (Norcross, GA) were used to 
perform flash chromatography. Reactions were monitored by thin-layer 
chromatography using precoated silica plates (F-254 (250 μm) from SiliCycle Inc; 
Quebec City, Quebec, Canada) and visualized using ninhydrin or KMnO4 staining 
or UV fluorescence. Fluorescein-modified PLGA was synthesized as described 
[23] 
3.2.2. Synthesis of PABC 
Step 1. Synthesis of phenyl (methoxy-L-alaninyl) phosphorochloridate:  
Phenyl (methoxy-L-alaninyl) phosphorochloridate was synthesized as previously 
described [16].  Briefly, phenyl dichlorophosphate (1 mol, 3.02 g) and L-alanine 
methyl ester hydrochloride salt (1 mol, 2.00 g) was suspended in anhydrous 
DCM, and cooled to -80 °C. To this mixture, a pre-cooled (-80 °C) solution of 
anhydrous trimethylamine (2 mol, 2.90 g) in DCM was added drop-wise, and the 
reaction was stirred and gradually warm to room temperature over 16 h under an 
inert argon atmosphere. The solvent was removed using a rotavap to yield a 
white solid that was resuspended into diethyl ether and filtered. The filtrate was 
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concentrated by rotavap to give colorless oil that was resuspended in anhydrous 
THF, and used without further purification for the subsequent coupling step. 
Step 2. Coupling of phenyl (methoxy-L-alaninyl) phosphorochloridate with 
ABC.  ABC (1 mol) was dried by azeotroping from anhydrous pyridine, then 
suspended in anhydrous THF and cooled to 0°C under argon. Tert-
butylmagnesium chloride (2 mol, 1.0 M solution in THF) was added to the mixture 
and stirring was continued for 10 min. Phosphorochloridate (3 mol, solution in 
THF) was added drop-wise to the deprotonated ABC and the reaction was stirred 
for 90 h at room temperature. The reaction was then cooled to 0°C and 
quenched with aqueous saturated ammonium chloride solution. The solvent was 
removed under vacuum, and the pure prodrug was isolated and purified using 
silica column chromatography. PABC was characterized using FTIR and 1H-NMR 
spectroscopy.  FTIR spectra of PABC was recorded and compared with that of 
ABC using a UATR-2 FTIR spectrometer (PerkinElmer Inc. Waltham, MA). 1H-
NMR spectra were recorded on a Varian INOVA 500 spectrometer. 1H-NMR data 
was recorded in ppm downfield using trimethylsilyl as an internal reference 
standard. 
3.2.3. Human Peripheral Blood Cell Isolation and Culture  
Human peripheral blood lymphocytes (hu-PBL) and monocytes were 
isolated by leukapheresis from HIV-1 and -2 and hepatitis seronegative donors, 
and purified by countercurrent as described previously [24]. For cellular uptake 
and antiretroviral efficacy studies monocytes were plated in 12-well culture plates 
at 1.5 X 106 cells / well and differentiated into macrophages (MDM) [25] by 
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culturing in DMEM with 1% glutamine, 10% heat-inactivated pooled human 
serum, 1000 U/ml MCSF, 10 μg/ml ciprofloxacin and 50 μg/ml gentamicin for 7-
10 days. Human peripheral blood lymphocytes were used for animal 
reconstitution as described below. 
3.2.4. Antiretroviral Activity of PABC 
The antiviral activity of PABC and native ABC against HIV-1 were 
determined in MDM [5]. MDM were incubated with various concentrations of ABC 
or PABC for 60 min followed by infection with HIV-1ADA at a multiplicity of 
infection (MOI) of 0.01 infectious viral particles/ cell for 4 h. The MDM were 
washed extensively with PBS to remove excess virus particles. The cells were 
incubated an additional 10 days in the presence of the same concentration of 
drug used before infection. Cell culture medium was changed every other day 
with replacement of equivalent drug containing media. At day 10 post infection, 
supernatants were collected and analyzed for HIV-1 reverse transcriptase (RT) 
activity [26]. 
3.2.5. Synthesis of Lipid-PLGA hybrid PABC Nanoparticles 
PBAC-loaded nanoparticles (NPs) of a mixed lipid outer shell and 
biodegradable PLGA inner core were prepared using the single - emulsion 
solvent evaporation method [27] and designated as lipid-nanoPABC (L-NPABC). 
PLGA and PABC (weight ratio 4:1) were dissolved in 2 ml of DCM to constitute 
the oil phase of the single emulsion.  For the aqueous phase DSPG, DSPE-
mPEG2k, and DSPC (weight ratio of 1:5:10) were dissolved in chloroform, 
followed by slow solvent evaporation and overnight drying in a vacuum 
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desiccator. The formed lipid film was hydrated with 8 ml phosphate buffer (10 
mM; pH 7.4) followed by vigorous mixing with vortex.  The oil phase was then 
added dropwise to the aqueous phase with stirring. The mixture was then cooled 
on an ice bath and sonicated using a probe sonicator (Cole Parmer, Vernon Hills, 
IL, USA) at 20% amplitude until the desired particle size of ~250 nm was 
achieved. The DCM from the emulsion droplets was evaporated using a Buchi 
Rotavapor (New Castle, DE). Unencapsulated drug and polymers were removed 
by centrifugation at 20,000 × g for 20 min. After washing three times, purified NP 
pellets were resuspended in 10 mM phosphate buffer (pH 7.4) with 0.2% w/v 
P407 poloxamer as cryoprotectant, followed by freeze-drying to obtain a fine 
powder. The control formulation without lipid outer covering was fabricated using 
5% polyvinyl alcohol (PVA) (w/v) as an emulsifier, and designated as NPABC. 
Fluorescently labeled L-NPABC were fabricated in the same manner using a 
mixture of fluorescein-labeled PLGA and unlabeled PLGA at a weight ratio of 3:1. 
The dye-labeled PLGA was synthesized as reported [23]. 
3.2.6. Physicochemical Characterization of PABC Nanoparticles 
3.2.6.1. Nanoparticle size and charge  
Size, size distribution (PDI) and surface charge of drug loaded NPs were 
measured by dynamic light scattering (DLS) using a Malvern Zetasizer, Nano 
Series Nano-ZS (Malvern Instruments Inc, Westborough, MA). Nanoparticle 
suspensions were diluted with water to optimize mass intensity then vortexed.  
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3.2.6.2. Nanoparticle morphology  
The morphology of drug loaded NPs was determined by scanning electron 
microscopy (SEM) on a Hitachi S4700 field-emission scanning electron 
microscope (Hitachi High Technologies America Inc, Schaumburg, IL, USA). 
Particle surface morphology and the outer shell lipid coating over the PLGA inner 
core were characterized by transmission electron microscopy (TEM) using a 
Hitachi H7500 Transmission Electron Microscope (Hitachi High Technologies 
America Inc, Schaumburg, IL, USA).  For TEM analysis, the NP suspensions 
were diluted in Milli-Q water and placed onto a copper grid, and air-dried at room 
temperature. For contrast enhancement, one drop of a 2% aqueous solution of 
sodium phosphotungstate was used as a negative stain. The images were 
recorded under bright-field conditions with exposure times of 2 s, and an 
accelerating voltage of 200 kV. 
3.2.6.3. Drug loading and encapsulation efficiency (EE) 
The amount of drug encapsulated in the polymeric matrix was determined 
by high performance liquid chromatography (Waters Breeze HPLC system, 
Waters Inc., Milford, MA, USA). Freeze-dried NPs (1 mg) were sonicated in 50 µl 
THF, diluted with 1 ml methanol, vortexed for 10 s, then centrifuged at 10,000 × g 
for 20 min. The supernatant was further diluted in mobile phase (35:65 v/v; 
acetonitrile/ 10 mM KH2PO4, followed by filtration using a 0.2 mm PVDF syringe 
filter. The sample components were separated on a Kinetex reversed phase C-
18 column ((5 µm, 150 × 4.6 mm), Phenomenex, Torrance, CA) using a flow rate 
of 1.0 ml/min. The column effluent was monitored at 220 nm. The percentage 
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drug loading was calculated as the weight percentage of PABC encapsulated in 
a given mass of lyophilized NPs. The EE was calculated as (actual amount of 
drug encased in NPs) / (initial amount of drug used in NPs preparation) × 100%. 
3.2.6.4. In vitro nanoparticle drug release   
The in vitro release profile of PABC from L-NPABC or NPABC was 
determined using dialysis [28].  Specifically, in triplicate the drug-loaded NPs 
were dispersed in 1 ml PBS (0.1 M, pH 7.4) and placed in a dialysis pouch 
(cellulose membrane, mw cut-off 10kDa) in 30 ml of PBS with stirring at 37 °C. At 
0.5, 1, 2, 4, 8, 12 and 48 h, 100 µl of the PBS was collected with replacement of 
an equal amount of fresh PBS. PABC in the aliquot was quantified by HPLC as 
described above. 
3.2.7. MDM Uptake of PABC Nanoformulations  
Uptake of PABC nanoformulations and free PABC were determined in 
human MDM [29, 30]. MDM were incubated with 100 µM free PABC or L-NPABC 
for various times from over 24 h. At each time point, MDM were washed 3 times 
with PBS to remove excess NPs or free drug. MDM were scraped into 1 ml of 
fresh PBS then pelleted by centrifugation at 950 x g for 8 min. The cell pellet was 
reconstituted in 200 µl of methanol, probe sonicated for 10 sec followed by 
centrifugation at 20,000 χ g for 10 min. The supernatant was analyzed for drug 
content using HPLC. Cytotoxicity of PABC or nanoformulated PABC was 
determined using MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide) [30]. Briefly, MDM were treated with 50, 100 and 200 µM free PABC or 
nanoformulated PABC for 24 h. Following washing with PBS, the MDM were 
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incubated with 200 µl of MTT working solution (0.5 mg/ml diluted in MCSF free 
media) for 30 min at 37°C.  Dimethyl sulfoxide (DMSO; 200 µl/well) was added to 
the cells and incubated for 5 min at 25˚C. The absorbance at 490 nm was 
measured using a SpectraMax M3 Microplate reader (Molecular Devices, 
Sunnyvale, CA, USA).  
3.2.8. Antiretroviral Activity of Nanoformulated PABC 
To determine antiretroviral activity of nanoformulated PABC, MDM were 
treated with 100 µM native ABC, free PABC or L-NPABC for 8 h. MDM were then 
washed 3 times with PBS to remove excess drug or NPs. On day 1, 5, 10 or 15 
following treatment, MDM were infected with HIV-1ADA at a MOI of 0.01 infectious 
viral particles /cell for 18 h. HIV-1 RT activity was measured in culture medium on 
day 10 post infection to determine viral replication [26]. As a secondary 
determinant of viral infection HIV-1 p24 protein expression in the MDM was 
determined by immunostaining [31].  
3.2.9. PABC Nanoparticle Subcellular Co-localization  
To evaluate the subcellular trafficking of nanoformulated PABC, human 
monocytes  (5 X 105 cells/ well) were cultured in an 8 well Lab-Tek II CC2 
chamber slide and differentiated into macrophages as described previously [31, 
32].  MDM were treated with 100 µM CF633-labeled L-NPABC for 8 h. The cells 
were washed 3 times with PBS to remove excess NPs. The cells were fixed with 
4% PFA for 30 min, permeabilized with 5% Triton-X in PBS for 15 min, and 
blocked with 5% BSA and 0.1% Triton-X in PBS for 15 min. The cells were 
washed with 0.1% Triton and incubated overnight at 4˚C followed by 1 h at room 
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temperature with primary antibody (1:50 dilution) against endocytic 
compartments; early endosomes (Rab5; sc-28570), late endosomes (Rab7; sc-
10767) and recycling endosomes (RAB11 and Rab14; sc-9020 and sc98610). 
The cells were washed with 0.1% Triton-X in PBS and incubated with 
corresponding AlexaFluor 488-conjugated secondary antibody for 90 min at room 
temperature. ProLong Gold anti-fade reagent with DAPI (4, 6-diamidino-2-
phenylindole) was added and the slide cover slipped.  Cells were imaged with an 
LSM 510 microscope using a 63X oil lens (Carl Zeiss Microimaging, Inc., Dublin, 
CA, USA).  
3.2.10. Pharmacodynamics  
For pharmacodynamics studies, 8-10 week old NOD/SCID/IL2Rγc −/− 
(NSG) mice were mice were obtained from a University of Nebraska Medical 
Center (UNMC) breeding colony. Breeding colony maintenance and animal 
pharmacodynamics studies were conducted according to protocols approved by 
the University of Nebraska Medical Center Institutional Animal Care and Use 
Committee. For pharmacodynamics studies, the mice were reconstituted with 
25×106 hu-PBL per mouse by intraperitoneal injection one week prior to 
treatment [33]. Following hu-PBL reconstitution, mice were treated with 100 
mg/kg of native ABC or an equivalent ABC dose of L-NPABC. Twenty-four hours 
after drug treatment, mice were injected intraperitoneally with HIV-1ADA using a 
104 tissue culture infectious dose 50(TCID50)/mouse.  Mice were sacrificed on 
day 10 post-infection, and blood and tissues were collected for fluorescence-
activated cell sorting (FACS), HIV-1p24 staining and viral load analysis. Blood 
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samples were collected into Ca2+-EDTA-coated tubes. The spleen cells were 
isolated at the time of sacrifice and suspended in PBS. The expression of human 
CD45, CD3, CD4 and CD8 immune markers was determined in blood and spleen 
cells using flow cytometry as previously described[34]. Splenic RNA was 
extracted using TRIzol (Invitrogen). Quantitative RT-PCR was conducted to 
determine the human CD45, mouse GAPDH RNA and HIV-1gag RNA levels.  
For HIV-p24 antigen staining, spleens were fixed in 10% neutral buffered 
formalin and paraffin embedded.  Serial 5 µm thick sections were cut, mounted 
on glass slides, and stained with human leukocyte antigen HLA-DR (dilution 
1:100) and mouse monoclonal antibodies for HIV-1p24 (1:10 dilution), 
respectively.  The antimouse, polymer based horseradish peroxidase-conjugated 
DAKO envision system was used as a secondary antibody for detection of HLA-
DR and HIV-1 p24 using 3, 3-diaminobenzidine (DAB). Mayer’s hematoxylin stain 
was used as a nuclear counterstain. The images were visualized with a Nikon 
Eclipse E800 microscope using NIS-Elements and a 40X objective.  The number 
of HLA-DR + and HIV-1p24+ cells per section were counted and expressed as 
the percentage of HIV-1p24+ cells per HLA-DR+ cells in a section.  
3.3. RESULTS  
3.3.1. PABC Synthesis and Characterization  
A phosphoramidate prodrug of abacavir (PABC) was synthesized to 
improve the biological activity of the parent nucleoside. The goal was to increase 
intracellular nucleoside 5’-O-triphosphate levels by circumventing the rate-limiting 
monophosphorylation of ABC by phosphotransferase as previously reported [5]. 
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This would lead to decreased activity of the virus encoded RT [16]. PABC was 
synthesized by derivatization of the native compound with an enzyme cleavable 
phosphorochloridate moiety (figure 3) following a previously reported method, 
[16]. The covalent linkage of phosphorochloridate to the 5’-O-hydroxyl group of 
ABC was confirmed by nuclear magnetic resonance, Fourier transform infrared 
spectroscopy and tandem mass spectrometry (1H-NMR, FTIR and MS/MS). As 
shown in Figure 3.2 A, the multiplet at 7.1-7.4 ppm in the 1H-NMR spectrum 
corresponds to five protons from the benzene ring of the derivatizing phosphate 
moiety. The singlet at 3.70 ppm and the two doublets at 1.38 ppm represent the 
three methyl ester protons and gamma protons from alanine on the phosphate 
group. Successful synthesis was validated by comparison of the FTIR spectra of 
PABC to that of native ABC (Figure 3.2 B). Peaks at 1739 cm-1 and 1208 cm-1 in 
PABC FTIR spectrum, corresponding to carbonyl (C=O) and phosphate group 
(P=O) stretching of the phosphochloridate moiety, confirmed the conjugation of 
phosphochloridate with the ABC molecule. The peaks at 1588 cm-1 in the PABC 
and ABC FTIR spectra corresponded to CH2 stretching of the native aromatic 
ring. Additionally, the peaks at 1035 cm-1 and 1021 cm-1 in the ABC and PABC 
spectra correspond to NH2 broadening of the parent compound. Infusion into a 
Waters Xevo TQS micro triple quadrupole tandem mass spectrometer confirmed 
a molecular mass ion of 528.2, which corresponds to ABC with one 
phosphochloridate modification (data not shown). The details for the 1H-NMR 
spectrum are; (CDCl3): 7.49 (2s, 1H), 7.1-7.4 (m, 5H), 6.05-6.15 (m, 1H), 5.87-
5.93 (m, 2H), 5.82 (br, 1H), 5.49-5.55 (m, 1H), 4.88 (br, 2H), 4.13-4.29 (m, 2H), 
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4.0-4.1 (m, 1H), 3.70 (s, 3H), 3.10-3.22(m, 1H), 3.01 (br, 1H), 2.73-2.85 (m, 1H), 
2.06 (br, 2H), 1.60-1.80 (m, 1H), 1.38 (2d, 3H), 0.80-0.90 (m, 2H), 0.63 (app s, 
2H). 
3.3.2. Antiretroviral Activity of PABC  
The antiretroviral activity of PABC compared to native ABC was 
determined in human MDM. MDM were treated with various concentrations of 
PABC or ABC bracketing  EC50 for ABC (100 nM) prior to and continuous with 
HIV-1ADA infection [5]. The HIV RT activity was assessed in infectious culture 
medium collected on day 10 day post-infection [26]. As shown in Figure 3.3 the 
EC50 for antiviral activity of PABC was improved 10-fold compared to native ABC. 
The EC50 for the PABC was ~15 nM compared to 150 nM for the native ABC. 
3.3.3. Preparation and Characterization of lipid-PLGA hybrid NPs 
Lipid-PLGA hybrid NPs loaded with PABC (L-NPABC) were synthesized 
using a modified single emulsion solvent evaporation technique as described 
previously [35]. A mixed lipid outer shell consisting of a 10:5:1 weight ratio of 
DSPC: DSPE-PEG2k: DSPG was incorporated over the drug loaded PLGA inner 
core to sustain the release of loaded cargo (Figure 3.5).  A 2:1 weight ratio of 
PLGA core to lipid shell was used. In contrast to its hydrophilic native counterpart 
(ABC), PABC was readily incorporated into PLGA NPs. The percentage drug 
loading using hydrophilic native ABC was less than 1% (data not shown). A 
control formulation, without the outer lipid layer, was synthesized using 5% PVA 
(w/v) as the emulsifier in the same manner as L-NPABC and designated as 
NPABC. NP size, charge and surface morphology were characterized by DLS, 
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SEM and TEM. Table 1 summarizes the characteristics of NPABC and L-
NPABC. The narrow PDI displayed by the nanoformulations indicates a relatively 
homogenous particle distribution. Furthermore, the morphology of L-NPABC, as 
determined by SEM and TEM, was observed to be spherical and around 200 nm 
in size, correlating with the size measured by DLS (Figure 3.4A, 3.4B). 
Examination of surface morphology by TEM confirmed an outer lipid covering 
over a PLGA core, potentially contributing to the sustained release of encased 
cargo [36]  (Figure 3.5). As shown in Figure 3.5, in contrast to NPABC, the lipid 
layer of L-NPABC enabled sustained release of PABC from the PLGA matrix.  A 
burst release was observed during the first 1 h for NPABC with more than 50% of 
drug released, and more than 95% of PABC released in the first 8 h. In contrast 
only 20% of PABC was released in the first 1 h for L-NPABC and less than 50% 
of PABC was released during the first  8 h., The cumulative PABC release 
reached 65% on day 1 and 73.5% on day 2 for L-NPABC compared to 95.2% on 
day 1 and 99.4% on day 2 for NPABC. Based upon the sustained drug release 
and improved drug encapsulation L-NPABC was selected for further in vitro and 
in vivo studies.  
3.3.4. Macrophage Uptake 
MDM uptake of L-NPABC and free PABC was determined over 24 h.  
MDM were exposed to 100 μM free PABC or L-NPABC for various times and 
drug uptake was quantified using HPLC.  As shown in Figure 3.6A, MDM uptake 
of PABC was maximum at 8 h for both free PABC and L-NPABC. At 8 h, the cell 
PABC levels for L-NPABC was 7.6 ± 0.8 μg/106 cells, which was 6-fold greater 
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than that for free drug (1.2 μg/106 cells). After 8 h, cell drug levels declined, and 
drug levels for L-NPABC and free drug at 24 h were 2.5 ± 0.3 and 0.32 μg/106 
cells, respectively. 
3.3.5. Antiretroviral Activity of PABC Nanoformulations 
To determine whether improved encapsulation and sustained release of 
PABC encased into L-NPABC would translate to improved antiretroviral activity 
compared to free PABC or native ABC, MDM were treated with 100 µM native 
ABC, free PABC or L-NPABC for 8 h. At day 1, 5, 10 or 15 post-treatment MDM 
were infected with HIV -1ADA.  HIV RT activity and HIV p24 antigen expression 
were assessed in infectious supernatant and adherent MDM on day 10 post-
infection. Decreased RT activity in MDM treated with nanoformulated PABC 
revealed that L-NPABC consistently decreased antiretroviral activity compared to 
that of free ABC or PABC. The RT activity was not decreased in the supernatant 
collected from MDM treated with native ABC, indicating either no uptake or rapid 
clearance of the native drug. However, HIV replication in MDM was suppressed 
by 95% using native ABC treated 24 h after HIV-1 exposure indicating drug 
penetration into the cells (data not shown).  HIV replication using free PABC was 
reduced by 100% at day 1 40 ± 5.4% at day 5, and minimal to no inhibition at 
days 10 and 15. In contrast L-NPABC suppressed viral replication by 100% at 
days 1 and 5 and 78 ± 3.5% and 52 ± 4.5% at days 10 and 15, respectively 
(Figure 3.6B). HIV p24 antigen expression in adherent MDM was assessed at 10 
day post infection to cross validate the results for RT activity. P24 antigen 
staining showed increased viral infection from days 1 to 15 in MDM treated with 
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free ABC or PABC, whereas minimal to no p24 antigen was detected in MDM 
treated with L-NPABC at all time points (Figure 3.6C ).  
3.3.6. Subcellular NPs Localizations  
Sub-cellular localization of fluorescein-labeled L-NPABC was determined 
using confocal microscopy. The physicochemical parameters of the fluorescein-
labeled L-NPABC were similar to that of the unlabeled nanoformulations (data 
not shown).  MDM were treated with 100 µM fluorescein-labeled L-NPABC for 
8h.  The cells were washed, fixed, and stained with Rab5, -7, -11, and -14 
endolysosomal protein antibodies as described previously [31, 32].  Rab5 and 
Rab7 antibodies identified the early and late endosomal compartments, whereas 
Rab11 and Rab14 antibodies identified recycling endosomal compartments. As 
shown in Figure 3.7A, the L-NPABC was co-localized predominantly in recycling 
endosomal compartments (Rab11 and Rab14), and observed as a yellow 
punctate pattern throughout the cytoplasm and perinuclear cell regions in the 
merged images of green compartments and red NPs.  The percent overlap 
between endosomal compartments and L-NPABC were determined using 
ImageJ software and JACoP plug-in.  L-NPABC showed significantly greater co-
localization with recycling endosomal compartments (38 ± 2.5% and 45 ± 1.5 %; 
Rab11 and Rab14) than with early and late endosomal compartments (17 ± 1.4 
% and 20 ± 2.3 %; Rab5 and Rab7) (Figure 3.7B ).  
3.3.7. Pharmacodynamics 
Antiretroviral efficacy of L-NPABC compared to native ABC was assessed 
in hu-PBL reconstituted NSG mice. Reconstituted mice were given a single 
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subcutaneous injection of 50 mg/kg of native ABC or an equivalent ABC dose of 
L-NPABC. Mice were infected with HIV-1ADA 24 h following treatment and viral 
replication was determined at day 10 post infection (Figure 3.8A). As a measure 
of HIV infection, the numbers of HIV-1 p24+ cells among HLA-DR+ cells were 
evaluated in paraffin-embedded spleen sections.  As shown in Figure 3.8B, 
compared to the untreated HIV infected controls, ABC treatment did not elicit 
protection from viral infection. In contrast, mice treated with L-NPABC showed a 
significantly lesser percentage of HIV-1p24+ cells per HLA-DR+ cells in spleen 
compared to untreated mice or mice treated with native ABC (Figure 3.8C). HIV-
1 infection results in a gradual decline of CD4+ T cells in hu-PBL reconstituted 
NSG mice [37-39].  Thus, as a measure of viral infection, the CD4+ /CD8+ T-cell 
ratios were determined using FACS analysis of spleen cells and blood cells 
collected at study termination. Decreased numbers of CD4+ T cells and CD4+ 
/CD8+ T-cell ratios were observed in spleens from mice infected with HIV-1 with 
no treatment or ABC treatment. However, the CD4+ /CD8+ T-cell ratios in 
spleens from mice treated with L-NPABC prior to HIV infection were not 
decreased. The CD4+ /CD8+ T-cell ratios in spleen from L-NPABC treated mice 
were significantly higher than in mice infected with HIV-1 with no treatment or 
ABC treatment and were comparable to those from uninfected control mice 
(Figure 3.8D). However, there were no significant differences in CD4+ /CD8+ T-
cell ratios among treatments groups and uninfected control mice in blood (data 
not shown). We also measured HIV-1gag RNA levels in spleen by reverse 
transcriptase polymerase chain reaction (RT-PCR) assay. L-NPABC treatment 
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suppressed HIV-1gag gene expression in spleen to 5 -folds. In contrast, 
treatment with native drug did not suppress HIV-1gag expression (Figure 3.8E).  
3.4. DISCUSSION 
Pronucleotides of ABC have been synthesized by others and provided two 
therapeutic advantages; (i) the direct administration of ABC-MP improved the 
antiviral efficacy in human macrophages and T-lymphocytes by circumventing 
the rate-limiting phosphorylation step and (ii) the deamination of ABC to CBV 
was bypassed, eliminating the CBV-associated renal and cardiac side effects [5]. 
Thus, direct administration of ABC-MP not only improved antiviral efficacy, but 
also improved the safety profile of ABC.  With these results in mind, we 
synthesized PABC with 54% final yield and validated the synthesis using 1H-
NMR, FTIR and mass spectrometry. The EC50 for HIV suppression was reduced 
10-fold in human MDM for PABC compared to native ABC (15 nM vs 150 nM, 
respectively). The improved antiviral potency of PABC compared to ABC is likely 
a consequence of the increased intracellular nucleoside 5-Oˊ-triphosphate level, 
which is limited by inefficient monophosphorylation of native ABC, as has been 
observed previously. In particular, metabolite studies have revealed that the 
phosphorylated ABC prodrug is metabolized predominantly to its active 
metabolite CBV-TP with no detectable CBV formation [5].  
Further optimization of the phosphorylated prodrug into an effective 
delivery system for long-term and targeted treatment of HIV was required. One 
such strategy would be to encapsulate the phosphorylated ABC prodrug into a 
polymeric nanocarrier to prolong drug half-life, improve pharmacodynamics and 
71 
 
facilitate drug delivery to restricted anatomical reservoirs of HIV-1 persistence 
[34, 40]. Lipid–polymer hybrid nanoparticles comprised of a polymer core (e.g., 
PLGA) and lipid/lipid-PEG shell have emerged as versatile carriers due to their 
unique composition, possessing both polymeric nanoparticle and liposomal 
characteristics [27]. PLGA, a biodegradable and biocompatible FDA approved 
polymer, is used to form the biodegradable core matrix, which is then wrapped by 
a shell of mixed lipids [41]. The PLGA core matrix encases the therapeutic pay-
load, whereas the mixed lipid monolayer ensures higher encapsulation and 
sustained release of the encased drug [42].  
In the present work we prepared PABC loaded PLGA/lipid hybrid 
nanoparticles to prolong the pharmacological activity of PABC. To demonstrate 
that the mixed lipid monolayer provided higher drug encapsulation and sustained 
released of loaded cargo a control PLGA formulation without the lipids outer-
layer (NAMC) was synthesized using PVA.  L-NPABC were slightly larger in size 
than NPABC (240 ± 12.0 nm and 208 ± 15.3 nm, respectively) likely due to the 
presence of the lipid layer on the surface of the PLGA core [27]. The highly 
negative ζ-potential of both nanoformulations provides electrostatic repulsion 
between the particles to reduce aggregation, and promote a relatively narrow 
size distribution [23].   Drug loading of both nanoformulations was less than 10%, 
however drug loading of the L-NPABC particles was slightly higher than for 
NPABC particles demonstrating that the benefit of the lipid monolayer shell. The 
higher loading can be attributed to formation of lipid vesicles that entrap a small 
amount of drug through hydrophobic interaction or hydrogen bonding [27]. L-
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NPABC also provided a more sustained drug release than PABC presumably 
due to the presence of a lipid bilayer acting to reduce PABC diffusion from the 
PLGA core. In addition to the lipid outer-layer, the PEG shield delays enzymatic 
degradation of PLGA matrix [43]. SEM showed that L-NPABC were spherical in 
shape with smooth surfaces, and TEM revealed the smooth covering of the outer 
lipid layer over the PLGA inner core.  These morphologies were similar to those 
reported previously for PLGA/lipid hybrid NPs [36].  
Mononuclear phagocytes (MP; monocytes, MDM and dendritic cells) have 
been shown by our and others studies to serve as drug reservoirs and 
carriersThese cells can facilitate drug carriage through their mobility, therapeutic 
cargo encasements and ability to home to viral target sites. To determine the 
effectiveness of this cell-based system for PABC nanoparticle storage and 
delivery human MDM were used to evaluate uptake, antiretroviral efficacy and 
subcellular trafficking L-NPABC.  Our results demonstrated that L-NPABC 
showed a significantly increased macrophage drug uptake compared to free 
PABC that was attributed to higher uptake of the nanoformulation via 
phagocytosis [44]. As a consequence of enhanced uptake of PABC, the L-
NPABC nanoformulations exhibited superior antiretroviral activity compared to 
free PABC or native ABC as measured by HIV RT activity and HIV-1 p24 antigen 
staining. The antiviral activity was maintained for 15 days after drug loading using 
L-NPABC, in contrast to 5 days for free prodrug and no protection for native drug. 
Previous work in our laboratory has shown that storage of nanoformulated 
antiretroviral drugs in late or recycling endosomal compartments of MDM 
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provides protection from drug metabolism in the same subcellular organelles that 
harbor HIV, and promotes sustained release of the encased therapeutic cargo.  
Co-localization of HIV and drug carrier in similar subcellular organelles boosts 
the antiretroviral activity of the drugs [31, 45]. Based upon these studies we 
determined whether L-NPABC would be trafficked similarly. Our results showed 
significantly higher co-localization of the L-NPABC in recycling endosomal 
compartments (Rab11 and Rab14) compared to early endosomes (Rab5) or late 
endosomes (Rab7). These results reflected the prolonged antiviral activity of L-
NPABC nanoformulations compared to native ABC or free PABC. Of importance, 
no cytotoxicity was observed in MDM at the concentration of L-NPABC 
nanoformulations or PABC used for these studies.  
These results suggested that sustained drug delivery and improved 
antiretroviral activity could be expected in vivo using L-NPABC. To determine 
whether L-NPABC could attenuate viral replication in vivo an acute HIV infection 
humanized mouse model was used. Hu-PBL-NSG mice were treated 
subcutaneously with L-NPABC or native ABC at equivalent doses, 24 h prior to 
HIV-1ADA infection. Ten days later HIV infection was determined using 
immunohistochemistry and RT-PCR. Our data demonstrated that mice treated 
with nanoformulated PABC showed less HIV-1p24 antigen in spleen compared to 
HIV positive controls and animals treated with ABC. ABC treatment did not 
provide protection from viral infection. Since, HIV-1 infection results in a gradual 
decline of CD4+ T cells in hu-PBL-NSG mice [37-39], we determined CD4+ and 
CD8+ T cell populations in the spleen and blood. Mice that were treated with free 
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ABC or not treated (HIV+ control) showed a significant loss in CD4+ T cells in 
spleen. In contrast, in mice treated with L-NPABC depletion in CD4+ T cells was 
prevented. In addition the CD4+ /CD8+ T-cell ratios of L-NPABC treated mice 
were significantly higher than in mice treated with free ABC or not treated. 
However, there were no significant differences in CD4+ /CD8+ T-cell ratios in 
blood between HIV-infected and drug treated, HIV-infected and non-drug treated 
and non-infected control mice (data not shown).  This could be related to the 
higher numbers of T-cells in the spleen, a viral reservoir compared to the blood in 
addition to the limitations in immune restoration within the hu-PBL-NSG HIV mice 
model [40]. Such limitations could be overcome by using CD34+ hematopoietic 
stem cell humanized mice, a chronic model of HIV infection [40]. As an additional 
measure of HIV replication, we determined HIV-1gag RNA levels in spleen by 
RT-PCR analysis.  We observed that L-NPABC treatment suppressed HIV-1 
replication to a greater extent compared to free drug or no treatment. These 
findings together suggest that the lipid coating over the PLGA core provides 
sustained release of PABC to prolong therapeutic activity.  
3.5. CONCLUSIONS 
We demonstrate that a phosphorylated prodrug of ABC (PABC) has 
improved antiretroviral activity over the native drug. The improved lipophilicity of 
PABC facilitated the encasement of the prodrug into PLGA nanoformulations with 
reasonable drug loading. Notably, coating the prodrug within a lipid-modified 
polymer matrix provided improved MDM uptake, retention and antiretroviral 
efficacy.  Nanoformulations localized to recycling endosomal compartments in 
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macrophages as has been previously observed for nanoformulated atazanavir 
and ritonavir [31]. Of importance, in a humanized mouse model of HIV infection, 
antiretroviral activity of PABC was extended over 10 days when encased into 
lipid-PLGA following a single SC dose. 
3.6 SUMMARY 
The quest amongst academics and pharmaceutical scientists in HIV/AIDS 
research to transform short-acting antiretroviral drugs into long-acting reservoir 
targeted medicines is substantive as the field aims to improve compliance while 
reducing viral resistance and toxicity. A means to achieve this end rests in 
manufacture of nanoformulated phosphoramidate prodrugs for nucleoside 
reverse transcriptase inhibitors as it would do all that as well as improve 
antiretroviral responses. Thus, we encapsulated phosphorylated abacavir 
(PABC) into mixed polymeric and lipid excipients to facilitate available 
intracellular nucleoside 5-Oˊ-triphosphates by bypassing rate-limiting parent drug 
monophosphorylation. We also reasoned that a long-acting nanoformulated 
PABC (NPABC) would improve ABC pharmacodynamics (PD) profiles. Herein, 
PABC was successfully synthesized then characterized by 1H-NMR and FTIR 
spectroscopy. PABC antiretroviral activities were compared to native ABC by 
assessment of its half maximal effective concentration50. A PABC was 
incorporated into a PLGA-lipid nanoformulation then assessed for structural 
stability, morphologic integrity, cytotoxicity, and attenuation of HIV-1 replication. 
The latter two were determined by viral p24 staining and reverse transcriptase 
activity.  Pharmacokinetic profiling was performed in Balb/C mice after a singular 
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intramuscular injection.  Preliminary pharmacodynamic evaluation was 
determined in human peripheral blood lymphocyte (hu-PBL) reconstituted 
NOD/scid-IL-2Rgc mice-infected with HIV-1ADA. Results demonstrated that 
antiretroviral responses were operative for ten days after single administration of 
in monocyte-derived macrophages and 10 days NPABC activity in virus-infected 
mice. These data, taken together, support the idea that antiretroviral responses 
could be achieved through intracellular delivery of NPABC. The PLGA-lipid 







Figure 3.1. Synthesis of PABC. PABC was synthesized in two steps as 
illustrated at a final yield of 62%; Phoshporochloridate moiety was synthesized 
using phenyl dichlorophosphate and L-alanine methyl ester (step 1); followed by 
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Figure 3.2.  Characterization of PABC. The purified PABC was characterized 
using (A) the 1H-NMR spectroscopy, which dictated the presence of a multiplet at 
7.1-7.4 ppm corresponding to five protons from the benzene ring of the 
derivatizing phosphate moiety. The singlet at 3.70 ppm and two doublets at 1.38 
ppm represent the three methyl ester protons and gamma protons from alanine 
on the phosphate group.  (B) Peaks at 1739 cm-1 and 1208 cm-1 in the PABC 
FTIR spectrum correspond to carbonyl (C=O) and phosphate (P=O) stretching of 
the phosphochloridate moiety, whereas the peak at 1588 cm-1 in ABC and PABC 
spectra corresponds to CH2 stretching of aromatic ring.   
PABC NMR.070.esp



































































                              
Figure 3.3. Antiviral activity of ABC and PABC against HIV-1ADA in human 
monocyte derived macrophages (MDM). MDM were exposed to various 
concentrations of ABC or PABC for 60 min, followed by challenge with HIV-1ADA 
at a multiplicity of infection of 0.01 infectious viral particles /cell for 4 h. HIV 
reverse transcriptase (RT) activity was measured on day 10 post infections. The 









 Figure 3.4. Synthesis and characterization of PABC loaded PLGA 
nanoparticles.  (A) Drug encased nanoparticles of mixed lipid outer shell and 
biodegradable PLGA inner core were prepared using the single-emulsion solvent 
evaporation method. (B) PABC encased PLGA hybrid nanoparticles were of 





Figure 3.4. Morphological analysis of drug PLGA nanoparticles. Morphology 
of nanoparticles was measured using (A) SEM and (B) TEM analysis. Images of 
L-NPABC revealed morphology and surface coating of lipids respectively.  The 







Figure 3.5. In vitro drug-release profile of PABC from PLGA matrix. The in 
vitro drug release of PABC was measured in Phosphate buffer (pH 7.4) at 37 °C. 
The cumulative drug PABC release from L-NPABC were measured and 
compared with NPABC (PLGA particles without lipid covering). At each time point 





Figure 3.6. MDM uptake and antiretroviral efficacy of ABC, PABC and L-
NPABC. (A) Drug and nanoformulation uptake was determined in MDM over 24 
h following treatment with 100 µM PABC or L-NPABC. Antiretroviral activity was 
determined in MDM treated with 100 µM native ABC, free PABC or 
nanoformulated PABC for 8 h, then infected with HIV-1ADA (MOI 0.1) at 1, 5, 10 or 
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15 days following drug loading. HIV replication was determined 10 days after 
infection by (B) HIV RT activity and (C) HIV p24 staining. For uptake studies, 








Figure 3.7.  Subcellular localization of nanoformulated PABC in MDM. MDM 
cultured in 8 well Lab-Tek II CC2 chamber slides were treated with 100 μM 
fluorescein labeled L-NPABC for 8 h then fixed and stained with antibodies to 
Rab 5, 7, 11 and 14. (A) Co-localization is observed as a yellow punctate pattern 
throughout the cytoplasm and perinuclear cell regions in merged images of red 
NPs and green subcellular compartments. (B) Percent fluorescence overlap was 
quantitated using ImageJ software, and JACoP plug-in. Statistical differences 






Figure 3.8. Antiviral activity of L-NPABC in hu-PBL-NSG mice. (A) Schematic 
illustration of ddIn vivo study; antiretroviral response comparing nanoformulated 
PABC to free ABC was performed in HuPBL reconstituted NOD/scid-IL-2Rgc 
(NSG huPBL) mice-infected with HIV-1ADA. Mice were subcutaneously injected 
with 100 mg/kg of ABC or equivalent dose using L-NPABC on day 1. Mice were 
infected with HIV-1ADA one day later and scarified on day 10 post infection. (B) 
Spleens were collected on day 10 after infection, then sectioned and 
immunostained with antibodies specific for HLA-DR or HIV-1p24, and visualized 
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by DAB. (C) Number of HIV-1p24+ cells per section were counted and expressed 
as percent of HLA-DR+ cells. (D) Immune profiles (CD4+/CD8+ T cell ratios) 
were determined in spleen cells, and (E) HIV1gag RNA copies were measured in 
spleens cells and normalized to human CD45 expression as a human cell 
marker. Data are expressed as mean ± SEM, and considered significant at p < 
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Table 3.1. Physicochemical characteristics of NPABC and L-NPABC.
 
Data 
represent mean ± SD, n= 3.  








NPABCb 208 ± 17 0.18 ± 0.05 -17.6 ± 1.7 4.5 ± 0.7
L-NPABCc 240 ± 10 0.22 ± 0.03 -21.6 ± 2.7 7.5 ± 0.4 
a Drug loading efficiency = (mg of PABC encapsulated in NP/ mg of lyophilized 
NP)×100. 
b NPABC = PABC-loaded within PLGA matrix  










CHAPTER 4. DEVELOPMENT AND 
CHARACTERIZATION OF A LONG-ACTING 




4.1. INTRODUCTION  
Treatment of human immunodeficiency virus (HIV) infection mandates 
early and lifelong treatment with combination antiretroviral therapy (cART) [1]. 
One impediment in reaching successful clinical outcomes is lack of adherence to 
cART drug regimens that serve to sustain reductions in viral load and maintain 
CD4+ T lymphocyte numbers [2, 3]. Maintaining cART drug levels is essential to 
protect susceptible cell populations and enable sustained antiviral responses to 
preclude the development of viral resistance [1]. Lack of achievement of LC/MS-l 
treatment outcomes rests in the inabilities of drugs to specifically target viral 
reservoirs [4]. These include gut-associated lymphoid tissue (GALT), lymph 
nodes, spleen, the central nervous system (CNS), and specifically central 
memory lymphocytes and myeloid cells contained within the lymphoreticular 
tissues [5-7]. Limitations in drug bioavailability have affected therapeutic 
outcomes [8]. All can lead to the perpetuation of viral sanctuaries and accelerate 
cART failures [9, 10]. We posit that the development of long-acting viral reservoir 
targeted nanoformulated ART (nanoART) can overcome such limitations while 
reducing drug toxicity and metabolism, improving drug targeting, and facilitating 
slow release of drug cell-carried cargos. These ultimately serve to improve 
antiretroviral drug pharmacokinetics (PK) and pharmacodynamics (PD) [11-15]. 
To such ends, our laboratory has pioneered the development of nanoART [16-
19]. Our nanoformulations show further improvements in design through ligand 
surface engineering [13, 19] serving to facilitate uptake into virus target cells. 
Mononuclear phagocytes (MP; monocytes, macrophages and dendritic cells) 
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serve as drug carriers. These cells facilitate drug carriage through their mobility, 
rapid delivery, cargo encasements, and abilities to deploy drug to viral target 
tissues [20]. To such ends, the ability of nanoART to home drug depots to viral 
reservoirs represents notable advantages over conventional therapy [21]. This 
explains the need for an interdisciplinary program serving to encapsulate 
antiretroviral drugs into polymeric nanoparticles for MP drug delivery and 
enabling PK and PD testing [16, 17, 19, 22]. 
 An obstacle toward success has been the difficulty in formulating the 
many available hydrophilic antiretroviral drugs into nanoparticles for parenteral 
administration. Thus, a platform was constructed to convert the drug abacavir 
(ABC) into a hydrophobic compound through esterification using myristic acid. Of 
interest, fatty acid analogues of myristic acid can inhibit N-myristoyltransferase, 
an enzyme that catalyzes myristoylation which is needed for activity of several 
proteins involved in the life cycle of HIV [23-27]. With this in mind, myristoylated 
ABC (called, MABC) was synthesized then formulated into nanosuspensions. 
This enabled the formation of hydrophobic drug crystals that were then placed 
into poloxamer-coated nanoparticles. Improved antiretroviral activity was 
observed for the modified ABC. Pro-longed antiretroviral activity was realized 
with the establishment of drug depots in Rab endosomes. Prolonged drug MP 
carriage and PK supports the opinion that MABC holds promise to extend the 




4.2. MATERIALS AND METHODS 
4.2.1. Chemicals  
ABC sulfate, myristic acid, poloxamer 407 (P407), folic acid (FA), and 
CF633-succinimidyl ester were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). ABC sulfate was converted into free-base using sodium bicarbonate. The 
chemical reactions were performed under a dry argon atmosphere. Flash 
chromatography was performed using 32-63 μm flash silica gels from Dynamic 
Adsorbents, Inc. (Norcross, GA, USA). Reactions were followed by thin-layer 
chromatography on precoated silica plates (250 μm) F-254 from SiliCycle Inc 
(Quebec City, QC, Canada). The compounds were visualized by UV 
fluorescence or by staining with ninhydrin or KMnO4 stains. High performance 
liquid chromatography (HPLC) grade methylene chloride, acetonitrile, methanol, 
dimethylformamide (DMF), LC/MS-grade water, and phosphate-buffered saline 
(PBS) were purchased from Fisher Scientific (Fair Lawn, NJ, USA). Rabbit anti-
human antibodies to LAMP1, Rab7, Rab11, Rab14, and AlexaFluor 488 
conjugated goat anti-rabbit IgG were purchased from Santa Cruz Biotechnology 
(Dallas, TX, USA). Folate-modified P407 (FA-P407) and CF633-modified P407 
were synthesized as described [20]. 
4.2.2. MABC Synthesis  
ABC (3.49 mmol, 1 equivalent) was dried by azeotroping from anhydrous 
pyridine, then suspended in anhydrous DMF and cooled to 0 °C under argon. 
Selective silylation of the 5-hydroxyl group of ABC was conducted by adding tert-
butyldimethylsilyl chloride (TBSCl) (4.18 mmol, 1.2 equivalents) and imidazole 
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(5.23 mmol, 1.5 equivalents) to the suspension with continuous stirring for 16 h 
after which the desired silylated product was isolated by flush chromatography 
purification and characterized by proton nuclear magnetic resonance (1H-NMR) 
spectroscopy. The amino group in the silylated ABC was then protected by 
reacting with methoxytriphenyl chloride (DMTr-Cl) (5.05 mmol, 2.2 equivalents) in 
anhydrous pyridine solvent to yield orthogonally protected ABC. Selective 
cleavage of the silyl group was achieved using tetra-n-butylammonium fluoride 
(4.87 mmol, 2.5 equivalents) to afford the free primary alcohol that was coupled 
with myristic acid (3.36 mmol, 2 equivalents) using 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4, 5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) (3.63 mmol, 2.2 equivalents) and N,N-
diisopropylethylamine (DIEA) (8.26 mmol, 5 equivalents) in DMF. Finally, 
cleavage of DMTr using trifluoroacetic acid produced MABC after purification; 1H-
NMR spectrum specifics: Rf 0.38 (9:1 CH2Cl2/MeOH); 
1H-NMR (500 MHz, CD3OD) 
δ 0.60-0.67 (br, 2H), 0.82-0.94 (m, 5H), 1.21-1.50 (br, 23H), 1.69-1.80 (m, 3H), 
2.60-2.74 (br, 1H), 2.82 (t, J = 8.6 Hz, 1H), 2.85 (t, J = 8.6 Hz, 1H), 2.96-3.12 (br, 
2H), 3.61 (dd, J = 5.3, 10.8 Hz, 1H), 3.68 (dd, J = 5.3, 10.8 Hz, 1H), 5.77-5.80 
(br, 1H), 5.92-5.98 (m, 1H), 6.16-6.33 (m, 1H), 8.01 (s, 1H). 
4.2.3. Antiretroviral Activity of MABC  
Human peripheral blood monocytes were obtained from HIV-1 and -2 and 
hepatitis seronegative donors and purified using counter-current centrifugal 
elutriation [28]. The monocytes were cultured and differentiated into 
macrophages (MDM) using DMEM with 10% heat-inactivated pooled human 
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serum, 1% glutamine, 50 μg/ml gentamicin, 10 μg/ml ciprofloxacin and 1000 U/ml 
MCSF for 7-10 days [29]. The antiviral activity of native drug and prodrug against 
HIV-1 was determined in human MDM at day 10 post-infection as described [30]. 
Briefly, MDM were exposed to various concentrations of ABC or MABC for 60 
min followed by challenge with HIV-1ADA at a multiplicity of infection (MOI) of 0.01 
infectious viral particles/cell. After 4 h of incubation, cells were washed three 
times with PBS to remove excess virus followed by incubation with the same 
concentration of drug used before infection. Cells were cultured for an additional 
10 days with half media changes every other day with equivalent replacement of 
drug containing media. Supernatants were collected at day 10 after viral 
infection, and the level of viral replication was determined by HIV reverse 
transcriptase (RT) activity [31]. 
4.2.4. Nanoformulated MABC (NMABC) 
Crystalline MABC was encased in poloxamer P407 (NMABC) using high-
pressure homogenization (Avestin EmulsiFlexC3; Avestin, Inc., Ottawa, ON, 
Canada) [16, 19]. Briefly, a suspension of 1% (w/v) MABC and 0.5% (w/v) P407 
in 10 mM HEPES buffer (pH 5.5) was premixed overnight at room temperature to 
generate drug containing polymeric micelles. Suspensions were then 
homogenized by high-pressure homogenization (20,000 PSI) until the desired 
particle size of ~250 nm was achieved. Folate-targeted nanoformulation (FA-
NMABC) was prepared in an analogous manner from a premix of 0.5% polymer 
as FA-P407 and P407 (60:40% w/w) [20]. Crude nanoformulations were purified 
by differential centrifugation at 5000 × g for 5 min to remove aggregated 
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particles. Further centrifugation at 20,000 × g for 20 min was used to remove the 
free MABC and polymeric micelles. Purified nanoparticle pellets were 
resuspended in 10 mM HEPES buffer (pH 5.5) for physicochemical 
characterization and for in vitro and in vivo studies. To prepare CF633-P407 
labeled nanoformulations, CF633-P407 and P407 were dissolved in methanol at 
a weight ratio of 1:5 [20, 32]. Methanol was then evaporated to generate a thin 
polymer film that was rehydrated using 10 mM HEPES buffer (pH 5.5) to yield a 
final excipient concentration of 0.5% (w/v). To this polymer solution, free MABC 
was added at a 1% (w/v) ratio. The suspension was protected from light and 
premixed at room temperature for 16 h. The suspension was homogenized and 
purified as described earlier for unlabeled formulations. CF633-labeled folate-
targeted nanoformulations were prepared similarly where CF633-P407, P407, 
and FA-P407 were dissolved in methanol at a weight ratio of 1:2:2. 
4.2.5. Physicochemical Characterizations of MABC and its Derivatives 
MABC was characterized using 1H-NMR and Fourier transform infrared 
(FTIR) spectroscopy. 1H-NMR spectra were recorded on a Varian INOVA 500 
mHz spectrometer (Varian, Inc., Palo Alto, CA, USA). 1H-NMR data is reported in 
ppm downfield from trimethylsilyl as an internal standard. FTIR spectra were 
recorded using a Spectrum Two UATR-Two FTIR spectrometer (PerkinElmer, 
Inc. Waltham, MA, USA). Nanoformulations were characterized for their particle 
size, polydispersity index (PDI), and zeta potential by dynamic light scattering 
(DLS) using a Malvern Zetasizer, Nano Series Nano-ZS (Malvern Instruments, 
Inc., Westborough, MA, USA). The morphology of the nanoformulations was 
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examined by scanning electron microscopy (SEM) using a Hitachi S4700 field-
emission scanning electron microscope (Hitachi High Technologies America, 
Inc., Schaumburg, IL, USA) [16]. Stability of the nanoformulation suspensions 
was assessed at room temperature (25 °C) and at 4 °C for a period of 8 weeks 
by measuring particle size and PDI by DLS. Drug loading, i.e. the weight 
percentage of MABC encapsulated in a given mass of lyophilized 
nanoformulation, was determined by UPLC-MS/MS (tandem mass spectrometry). 
To determine drug concentration in purified nanosuspensions, an aliquot of the 
nanosuspension was extracted using methanol and analyzed by UPLC-MS/MS 
[20].  
4.2.6. Nanoparticle MDM Uptake and Retention  
Uptake and retention of nanoformulations were determined in human 
MDM [16, 33]. Briefly, MDM were treated with nanoformulations at a 
concentration of 100 µM MABC. Cell uptake was assessed at different time 
points without any media changes. At each time point, adherent MDM were 
washed three times with 1 ml of PBS, scraped into 1 ml of fresh PBS and 
pelleted by centrifugation at 950 x g for 8 min. The cell pellet was reconstituted in 
200 µl methanol and probe sonicated followed by centrifugation at 20,000 x g for 
20 min. The supernatant was analyzed for drug content using UPLC/MS-MS.  
To determine involvement of folate receptors (FOLR) in MDM uptake of 
the folate-targeted nanoformulation, cells were pre-incubated with 50 µM free 
folic acid for 60 min prior to treatment with 100 µM FA-NMABC. For cell retention 
studies, MDM were treated with 100 µM of nanoformulated MABC for 8 h; cells 
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were then washed with PBS to remove free drug or unincorporated 
nanoparticles, followed by further incubation in MCSF-free medium without 
nanoformulation. At days 1, 5, 10, and 15, cells were washed, collected, and 
analyzed for drug content as described for uptake studies. Cell viability was 
determined using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
(MTT) [16]. Briefly, MDM were treated with 10, 50, 100, and 200 µM NMABC or 
FA-NMABC for 24 h. The adherent cells were washed with PBS, and 200 µl of 
MTT working solution (0.5 mg/ml diluted in MCSF free media) was added to the 
cells followed by incubation at 37 °C for 30 min and washing with PBS. DMSO 
(200 µl/well) was added to the cells and incubated for 5 min at 25 °C. The 
absorbance at 490 nm was measured using a SpectraMax M3 Microplate reader 
(Molecular Devices, Sunnyvale, CA, USA).  
4.2.7. Antiretroviral Activity of MABC Nanoformulations 
MDM were treated with 100 µM MABC using free MABC or 
nanoformulations for 8 h. The cells were washed with PBS to remove excess free 
drug and nanoparticles. The MDM were challenged with HIV-1ADA at a MOI of 
0.01 infectious viral particles /cell for 18 h on day 1, 5, 10, and 15. Progeny virion 
production was measured by RT activity in culture medium [31]. HIV-1 p24 
protein expression was assessed in adherent cells [32]. The cells were washed 
with PBS and fixed with 4% paraformaldehyde (PFA) for 15 min at room 
temperature. The cells were blocked using 10% bovine serum albumin (BSA) 
containing 1% Triton X-100 in PBS for 30 min at room temperature. Following 
blocking, cells were incubated with HIV-1 p24 mouse monoclonal antibodies 
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(1:50; Dako, Carpinteria, CA, USA) for overnight at 4 °C, followed by 1 h 
incubation at room temperature. HRP-labeled polymer anti-mouse secondary 
antibody (Dako EnVision® System; Dako, Carpinteria, CA, USA) was added (one 
drop/well). Hematoxylin (500 µl per well) was added to counterstain the nuclei, 
and images were captured using a Nikon TE300 microscope with a 20X 
objective. 
4.2.8. MABC Nanoparticle Subcellular Localization  
To determine subcellular localization of nanoformulated MABC, human 
monocytes were cultured in an 8 well Lab-Tek II CC2 chamber slide at a density 
of 5 X 105 cells/well and differentiated into macrophages as described previously 
[20]. MDM were treated with 100 µM of MABC using CF633-labeled NMABC or 
FA-NMABC for 8 h, washed with PBS, fixed, and stained using subcellular 
compartment antibodies [20, 32]. Briefly, cells were fixed with 4% PFA for 30 min 
at room temperature, permeabilized using 5% Triton-X in PBS for 15 min, and 
blocked with 5% BSA and 0.1% Triton-X in PBS. The cells were then incubated 
overnight at 4 °C for 1 h at room temperature with primary antibody (1:25 dilution 
in 5% BSA and 0.1% Triton-X in PBS) for respective endocytic compartments: 
late endosomes (Rab 7; sc-10767), recycling endosomes (RAB11 and Rab14; 
sc-9020 and sc98610), and lysosomes (LAMP1; sc-5570). The cells were 
washed extensively using 0.1% Triton-X in PBS and subsequently were 
incubated with secondary antibody conjugated with AlexaFluor 488 for 60 min at 
room temperature. The cells were covered with ProLong Gold anti-fade reagent 
with DAPI I (4,6-diamidino-2-phenylindole), cover slipped, and imaged with an 
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LSM 510 microscope using a 63X oil lens using an LSM 510 confocal 
microscope (Carl Zeiss Microimaging, Inc., Dublin, CA, USA). 
4.2.9. PK Studies 
Animal PK studies were conducted in accordance with the University of 
Nebraska Medical Center Institutional Animal Care and Use Committee (IACUC). 
Male Balb/cJ mice (Jackson Labs, Bar Harbor, ME, USA) were maintained on a 
folate deficient diet (Harlan Teklad TD.00434; Harlan Laboratories, Inc., 
Indianapolis, IN, USA) for two weeks prior to treatment and throughout the study. 
Mice were injected intramuscularly (IM) with 50 mg/kg ABC equivalents using 
native ABC, NMABC, or FA-NMABC in PBS. On days 1, 3, 5, 7, 9, 12, and 14 
after drug treatment approximately 50 µl blood was collected by cheek bleeding, 
and immediately 40 µl was added into 1 ml of acetonitrile for drug analysis. 
Internal standard (IS; 10 µl) was added to each sample and consisted of 0.665 
µg/ml d4-ABC, and 0.5 µg/ml lopinavir. Samples were centrifuged at 17,000 x g 
for 10 min, and supernatants were dried using a ThermoScientific Savant Speed 
Vacuum (ThermoScientific, Waltham, MA, USA), reconstituted in 100 µl of 80% 
v/v methanol in LC/MS- 
UPLC-MS/MS analysis. Thirty µl of the reconstituted samples were diluted with 
50 µl water for ABC UPLC-MS/MS analysis. Final concentrations for both d4-ABC 
(IS for ABC) and lopinavir (IS for MABC) were 50 ng/ml. Standard curves of ABC 
or MABC were prepared similarly, in blood collected from control mice in the 
range of 0.35-3500 ng/ml and 0.125-1250 ng/ml, respectively. A Waters 
ACQUITY H-class UPLC system (Waters, Milford, MA, USA) connected to a 
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Waters Xevo TQS-micro mass spectrometer with electrospray ionization (ESI) 
source was used for drug quantitation. Chromatographic separation of 10 µl ABC 
sample injections was achieved on an ACQUITY UPLC CSH C18 column (1.7 
µm, 100 mm x 2.1 mm) using a 13 min gradient of mobile phase A (7.5 mM 
ammonium bicarbonate in grade water, adjusted to pH 7 with glacial acetic acid) 
and mobile phase B (100% LC/MS- grade methanol) at a flow rate of 0.25 
ml/min. The initial mobile phase composition was 10% B for the first 2.5 min and 
was gradually increased to 95% B in 6.5 min and held constant for 1.5 min. 
Mobile phase B was then reset to 10% in 0.45 min, and the column was 
equilibrated for 2.25 min before the next injection. MABC chromatographic 
separation was achieved using the same CSH C18 column and mobile phases 
but with a 16 min isocratic method using 81% mobile phase B and flow rate of 
0.3 ml/min. ABC and MABC were detected at a cone voltage of 8V and 16 V, 
respectively, and a collision energy of 16 V and 30 V, respectively, in the positive 
ionization mode. Multiple reaction monitoring (MRM) transitions used for ABC, 
MABC, d4-ABC, and lopinavir were 287.14 > 191.00, 497.18 > 191.07, 291.14 > 
79.02, and 629.18 > 447.2 (m/z) respectively. Spectra were analyzed and 
quantified by MassLynx software version 4.1. All calculations were made using 
analyte peak area to internal standard peak area ratios. 
4.2.10. Statistical Analyses 
Drug uptake and retention data were analyzed by one-way analysis of 
variance (ANOVA) and Student's t-test using GraphPad Prism software 
(GraphPad Software, Inc., La Jolla, CA, USA). Confocal images were analyzed 
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as percent overlap using ImageJ software with JACoP plugin to quantify the 
amount of overlap between labeled nanoparticles and labeled endocytic 
compartments. Differences of mean percent overlap between nanoformulations 
were analyzed using Student's t-test. Experiments were performed three times 
unless otherwise specified. Animal studies were conducted with five animals per 
treatment group. Statistical analysis was performed by 2-way ANOVA and 
Bonferroni’s Multiple Comparison test. Results are expressed as mean ± 
standard error of mean. Results were considered significant at a p value < 0.05. 
4.3. RESULTS 
4.3.1. MABC Synthesis and Characterization  
In its native form, ABC has restricted intracellular and tissue penetrance 
[30, 34]. Its hydrophilic nature also poses challenges for nanoformulation 
preparations. To facilitate encapsulation of ABC into a poloxamer-stabilized 
nanosuspension, MABC, a hydrophobic prodrug of ABC, was synthesized. This 
was accomplished through derivatization of the native compound with a 
cleavable fatty acid ester (Figure 4.1). Covalent linkage of myristic acid to the 5’-
O-hydroxyl group of ABC was confirmed by nuclear magnetic resonance, Fourier 
transform infrared spectroscopy and tandem mass spectrometry (1H-NMR, FTIR 
and MS/MS). Specifically, the triplet at 2.36 ppm in the 1H-NMR spectrum of 
MABC represents two fatty acid methylene protons adjacent to the carbonyl 
group linked to ABC, while the broad multiplet signal in the region of 1.21-1.50 
ppm of the spectrum corresponds to 20 hydrogens of the repeating methylene 
units of the fatty acid chain (Figure 4.2A). This was confirmed by comparing FTIR 
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spectra of MABC to that of native ABC and myristic acid (Figure 4.2C). The 
presence of alkane stretching (CH2-CH2) peaks at 2915 cm
-1 and 2850 cm-1 in 
the FTIR spectrum of MABC confirmed that the alkane chain of the derivatizing 
fatty acid (2913 and 2847 cm-1) with the parent drug occurred. The peaks at 1595 
cm-1 in MABC and 1588 cm-1 in the ABC FTIR spectra corresponded to CH2 
stretching of the native aromatic ring. Peaks at 1673 and 1696 cm-1 in MABC and 
myristic acid corresponded to C=O fatty acid attachments. The peak at 1033 cm-1 
and 1030 cm-1 in ABC and MABC spectra corresponded to NH2 broadening of 
the parent compound. Infusion into a Waters Xevo TQS micro mass 
spectrometer confirmed a molecular mass ion of 496.2, which corresponds to 
ABC with one myristoyl group (data not shown). 
4.3.2. Antiretroviral Activity of MABC 
The antiretroviral activities of MABC and native drug were compared in 
MDM. Various concentrations of ABC or MABC bracketing the EC50 for ABC 
were added to MDM prior to and continued with HIV-1ADA infection [30]. 
Antiretroviral activity was determined by measuring RT activity in culture fluids 
collected 10 days after drug treatment and infection. The antiviral activity of 
MABC as determined by the EC50 for viral suppression was comparable to that of 
the parent drug (̴ 100 µM) (Figure 4.3).  
4.3.3. Preparation and Physicochemical Characterization of the NMABC  
Poloxamer nanoformulations of MABC were prepared by high-pressure 
homogenization as previously described [16, 18]. Nanoparticles in suspension 
were characterized by DLS and SEM. The physicochemical parameters of 
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NMABC and FA-NMABC nanoparticles were similar. The size, PDI, and zeta 
potential of NMABC nanoparticles were 160 ± 10 nm, 0.2 ± 0.1, and −27.5 ± 2.5 
mV, respectively. Similarly, the size, PDI and zeta potential of FA-NMABC 
nanoparticles were 170 ± 12 nm, 0.15 ± 0.04, and −33.7 ± 3.7 mV, respectively. 
Relatively low PDI values displayed by the two nanoformulations indicated a 
narrow particle size distribution within the suspensions. Morphologically both 
NMABC and FA-NMABC were observed to be cylindrical rods of 200 nm in size 
as determined by SEM, correlating with particle size determined by DLS (Figure 
4.4A & B). The stability of nanoformulations over time and temperature was 
assessed by measuring the NMABC particle sizes over a period of 8 weeks at 4 
°C and 25 °C. During this time, the size and PDI did not change significantly at 
either of the two temperatures (Figure 4.4C & D), an indication that the 
nanoformulations remained stable for at least two months. Drug loading for 
NMABC and FA-NMABC nanoformulations was found to be 62 ± 1.5 and 65 ± 
2.4% respectively. Lyophilized formulation powders were also characterized by 
magnetic resonance spectroscopy in DMSO. The presence of a singlet at 3.7 
ppm in the 1H-NMR spectrum of the formulation corresponds to the repeating 
methylene- units (next to oxygen) of the polymer. Peaks corresponding to the 
myristoylated prodrug protons were also evident in the formulation spectrum. 
4.3.4. Nanoformulated Drug Uptake and Retention  
To determine whether FOLR targeting would enhance MDM uptake and 
consequently retention of MABC, MDM were treated with 100 µM MABC using 
NMABC or FA-NMABC for up to 8 h. MDM uptake of nanoformulated MABC 
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increased over time and reached a maximum at 8 h. As shown in Figure 4.6A, an 
up to 2.5-fold increase in uptake was observed for FA-NMABC compared to 
NMABC. Cell MABC concentrations for FA-NMABC nanoformulations were 5.12 
± 0.2, 11.3 ± 0.3, 19.07 ± 1.2, and 24.7 ± 1.5 µg/106 cells at 1, 2, 4, and 8 h, 
compared to 2.1 ± 0.1, 3.5 ± 0.2, 8.6 ± 1.2, and 11.3 ± 1.5 µg/106 cells for 
NMABC formulations at the same time points. In order to deduce whether 
improved uptake of FA-NMABC was mediated by the FOLR, MDM were 
incubated with excess free folic acid (50 µM) prior to treatment. As shown in 
Figure 4.6A, blocking FOLR with excess folic acid decreased FA-NMABC uptake 
to levels similar to that of NMABC. Substantial (1.5 to 3 orders of magnitude) 
differences were observed in the extent of MABC retention in MDM over 15 days 
with FA-NMABC compared to NMABC, reflecting the initial enhanced uptake 
using the folate-targeted nanoformulation (Figure 4.6B). The uptake and 
retention of MABC using FA-NMABC was significantly greater than that observed 
for NMABC (Student’s t-test, **P < 0.001). The concentration of nanoformulations 
used (100 µM) did not induce cell toxicity as determined by the MTT assay (data 
not shown). 
4.3.5. Antiretroviral Activities of Nanoformulated MABC  
To determine whether improved hydrophobicity of MABC and subsequent 
improved uptake and retention in MDM using MABC nanoformulations would 
translate into improved antiretroviral activity, MDM were treated with 100 µM 
native ABC, free MABC, NMABC or FA-NMABC for 8 h. Following treatment, 
MDM were challenged with HIV-1ADA at an MOI of 0.1 on days 1, 5, 10, and 15 
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post-treatment. Decreased RT activity in infectious supernatants collected on day 
10 post-infection revealed that FA-NMABC exhibited enhanced antiretroviral 
activity compared to NMABC or free MABC (Figure 4.7A). RT activity was not 
decreased in supernatants collected from MDM treated with native ABC, 
suggesting either no uptake or rapid metabolism of the native drug. However, 
native ABC suppressed HIV RT activity by 100 and 95% when cells were treated 
12 and 24 h after HIV-1 exposure (data not shown). HIV replication using FA-
NMABC was suppressed by 100 ± 2.3% at days 1 and 5 and by 88 ± 3.4 % and 
70 ± 2.5% at days 10 and 15; whereas, NMABC suppressed viral replication by 
100 ± 1.5%, 78 ± 1.7%, 72 ± 3.5%, and 52 ± 4.5% at days 1, 5, 10 and 15, 
respectively. Minimal or no inhibition was achieved using free MABC (Figure 
4.7A). RT activity was cross-validated by evaluating HIV-1 p24 antigen 
expression in adherent MDM 10 days post-infection. MDM treated with free 
MABC or NMABC showed increased viral infection from days 1 to 15, as 
observed by the intensity of brown staining of p24 antigen; whereas, minimal to 
no p24 antigen was detected in MDM treated with FA-NMABC measured at all 
time points (Figure 4.7B).  
4.3.6. Subcellular Nanoparticle Localizations  
Sub-cellular localization of the nanoformulations taken up by MDM was 
assessed using confocal microscopy. MDM were treated with 100 µM CF633-
labeled NMABC or FA-NMABC for 8h. Physicochemical parameters for CF633-
labeled nanoformulations were similar to that of unlabeled nanoformulations 
(data not shown). After incubation, cells were washed, fixed, and stained with 
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antibodies to endosomal compartments as described [20, 32]. Rab7 antibody 
identified the late endosomal compartments, Rab11 and Rab14 antibodies 
identified compartments involved in recycling, and LAMP1 (lysosomal-associated 
membrane protein 1) antibody identified the lysosomal compartments. Co-
localization was seen as a yellow punctate pattern throughout the cytoplasm and 
perinuclear cell regions in the merged images of red nanoparticles and green 
compartments. For both nanoformulations co-localization was found 
predominantly in recycling endosomes compared to late endosomal and 
lysosomal compartments (Figure 4.8A). Percent overlap between endosomal 
compartments and nanoformulations, as determined using ImageJ software and 
JACoP plug-in, showed greater co-localization of nanoparticles with recycling 
endosomal compartments (46 ± 2.4% and 62 ± 1.5%, Rab11 and Rab14 for 
NMABC; 70 ± 1.7 and 79 ± 4.3, Rab11 and Rab14 for FA-NMABC) than with 
lysosomal and late endosomal compartments (27 ± 1.8 % and 36 ± 2.3 %, 
LAMP1 and Rab7 for NMABC; 34 ± 3.2 and 64 ±2.8, LAMP1 and Rab7 for FA-
NMABC) (Figure 4.8B). FA-NMABC exhibited significantly greater co-localization 
with all compartments compared to NMABC (*P < 0.05). 
4.3.7. PK Studies 
To determine whether improved hydrophobicity and encapsulation of 
MABC into poloxamer nanoformulations would translate into sustained blood 
ABC drug levels in vivo, mice were injected IM with 50 mg/kg of native ABC or an 
equivalent ABC dose as NMABC or FA-NMABC. Mice have approximately 10-
fold higher free folate levels than humans, and excess folate may block the 
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FOLR and interfere with rapid uptake of FA-targeted nanoformulation [35]. Thus, 
prior to treatment, mice were placed on folate-deficient diet for 2 weeks to reduce 
plasma folate levels [18]. For ABC and MABC analysis, whole blood was 
collected immediately into acetonitrile to inhibit the activity of esterases, which 
would cleave the myristoyl group from MABC, and adenosine deaminase, which 
could convert ABC to carbovir [30]. ABC blood levels measured at days 1, 3, 5, 
7, 9, 12, and 14 post treatments were significantly higher in mice treated with FA-
NMABC compared to those treated with NMABC or native ABC. MABC was 
lower than the limit of quantitation (< 0.125 ng/ml) in all samples, indicating rapid 
conversion of the MABC to ABC in blood. By day 14, ABC blood levels were 36 ± 
4.7ng/ml, 21 ± 3.8 ng/ml, and below the limit of quantitation (0.5 ng/ml) in mice 
treated with FA-NMABC, NMABC and native drug, respectively (Figure 4.9). 
4.4. DISCUSSION 
Currently, the nucleoside reverse transcriptase inhibitor ABC is 
recommended as a component of a first line treatment regimen by the National 
AIDS Control Organization [36]. In combination with two other NRTIs, for 
example, zidovudine and lamivudine (3TC) such as Trizivir, it is part of a three-
drug antiretroviral regimen [36, 37]. Notably, viral strains that are resistant to 
zidovudine or 3TC can be sensitive to ABC [38]. However, ABC is associated 
with a dose dependent hypersensitivity response that may lead to death if 
therapy is not discontinued, and patients must be pre-screened for the HLA-
B*5701 allele [39]. ABC can be used as an alternative to Truvada in pre-
exposure prophylaxis (PrEP) drug regimens used in the management of HIV-1 
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transmission [40, 41]. Trizivir and other combination therapies lead to decreased 
viral resistance and improved long-term survival. Currently, ABC, 3TC, and 
dolutegravir are recommended as the most effective ART regimen [42]. However, 
the short half-lives of the current regimens and the intrinsic physicochemical 
properties of these antiretroviral drugs have limited their utilities and hence 
demonstrate the need for long acting delivery platforms that can improve patient 
adherence and facilitate drug entry into restricted anatomical reservoirs of HIV-1 
persistence [15]. While progress has occurred towards developing long acting 
nanoformulations for protease and non-nucleoside RT inhibitors [16, 19, 20, 43] 
development of nanoformulations of hydrophilic drugs has remained elusive. 
Attempts have been made to encapsulate ABC into polymeric nanomedicines but 
poor loading and fast release kinetics have hampered their clinical applicability 
[44].  
To overcome such challenges, a carboxylic acid ester prodrug approach 
has been widely used to improve lipophilicity and oral absorption of nucleoside 
analogs [23, 45]. In this approach, a carboxylic acid containing hydrophobic alkyl 
chain is reacted with the hydroxyl group located at the five membered ring moiety 
of the nucleoside analog. Even though the carboxylic acid ester prodrug 
approach has been used to modify a variety of anticancer compounds [46, 47] 
and antiviral drugs [48], development and nanoformulation of hydrophobic 
derivatives of antiretroviral drugs such as 3TC and ABC remain elusive. The goal 
of the present study was to improve the half-life and therapeutic efficacy of ABC 
through derivatization of the highly water soluble parent drug with a hydrophobic 
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fatty acid side chain to generate a myristoylated prodrug that would be easily 
encapsulated into polymer excipients and other surfactants to target 
macrophages. The 5-hydroxyl group on the cyclopentene moiety of ABC was 
esterified with myristic acid, a 14 carbon chain fatty acid. MABC was successfully 
synthesized at a final yield of 66% after purification and characterized using 1H-
NMR and FTIR spectroscopy. In the cell, MABC was converted to ABC by 
esterase cleavage followed by phosphorylation to produce the therapeutically 
active compound [30]. The success of such a strategy has been shown for CP-
4126, a fatty acid prodrug of gemcitabine, which upon cleavage by esterases 
resulted in a 200-fold increase in therapeutic activity [46]. Our results 
demonstrated that prodrug synthesis does not impair the antiretroviral activity of 
parent ABC, as determined by RT activity.  
Over the past decade, work from our laboratory has demonstrated the 
potential of targeted nanoART to produce sustained high plasma and tissue drug 
concentrations for weeks following a single IM administration that can suppress 
ongoing viral replication and mitigate dose associated viral resistance [17, 19]. In 
this context, nanoART was manufactured using folate-conjugated P407 that 
targets the FOLR2 expressed on activated macrophages [20]. Macrophage 
activation and subsequent overexpression of FOLR2 can be induced by folate-
conjugated therapeutics [49]. Our results demonstrated that P407 and FA-P407 
coating of MABC produced stable nanoformulations of similar physicochemical 
parameters. The drug loadings for both nanoformulations were high (62-65% 
w/w), which offers the advantage of administering a dose with less non-active 
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excipients. Since the geometry of nanoparticles plays an important role in 
determining attachment to the macrophage surface [50], the morphology of the 
MABC nanoformulations was analyzed using SEM. Our results demonstrated 
that the morphology for both NMABC and FA-NMABC nanoparticles was 
cylindrical rods, which is advantageous in terms of macrophages uptake. The 
mechanism reflects the preference of macrophages for engulfment of most 
bacteria that have a rod shaped geometry in nature [51]. 
In the case of folate targeting, receptor-mediated endocytosis occurs 
through interaction of folic acid moieties present on FA-nanoART with FOLR 
present on the macrophage surface [20]. Our results demonstrated that FA-
NMABC nanoformulations showed a significantly increased macrophage uptake 
through binding to the FOLR compared to non-targeted NMABC. Indeed, folate-
mediated uptake was cross validated by the inhibition of FA-NMABC uptake by 
blocking the FOLR with excess free folic acid (Figure 4A). When FOLR were 
blocked, the uptake of FA-NMABC by MDM was significantly decreased to a 
level similar to that for NMABC demonstrating that the superior uptake of folate 
nanoformulations occurred through engagement of the FOLR. Consequently, the 
amount of MABC that was retained in MDM using FA-NMABC was greater 
compared to that for NMABC nanoformulations (Figure 4B). MDM retained more 
than 2-fold greater levels of FA-NMABC than NMABC over a period of 15 days. 
As a consequence of enhanced uptake and retention of MABC, the FA-NMABC 
nanoformulations exhibited superior antiretroviral activity compared to NMABC 
nanoformulations as measured by RT activity and HIV-1 p24 antigen staining 
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(Figure 4C & D). The protection of MDM from HIV-1ADA infection was observed 
for 15 days using folate-targeted nanoformulations, in contrast to reduction in 
protection by 5-10 days for non-targeted formulations and free drug. Thus, 
sustained drug delivery and improved antiretroviral activity of MABC might be 
expected in vivo using folate-coated nanoformulations. In addition, no cytotoxicity 
was observed in MDM at the nanoformulations concentration tested. 
Our laboratory demonstrated previously that storage of nanoART in late or 
recycling endosomal compartments provides a protected environment for the 
encased cargo in the same subcellular organelles that harbors the pathogen and 
promotes slow release of the encapsulated drugs. Similar subcellular trafficking 
pathways for nanoparticles and HIV would enhance the antiretroviral response of 
the drugs [32, 52]. In this study, subcellular localization of MABC 
nanoformulations was investigated in MDM. Our results showed greater co-
localization of the MABC nanoformulations in recycling endosomal compartments 
(Rab11 and Rab14) compared to late endosomes (Rab7) or lysosomes (LAMP1) 
(Figure 5). For each compartment, the uptake of folate-targeted nanoformulation 
was significantly higher compared to non-targeted nanoformulation. These 
results reflect the higher overall uptake and greater antiviral efficacy of FA-
NMABC compared to NMABC. However, some nanoparticles were localized in 
the degrading lysosomal compartments. Therefore, future studies will focus on 
minimizing the amount of nanoparticles trafficked into the lysosomal 
compartments to further improve the antiretroviral outcomes. 
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To determine whether FA-NMABC compared to NMABC or free drug 
could provide sustained blood drug levels, mice were treated with 50 mg/kg of 
ABC as free drug or MABC nanoformulations. Blood drug levels of ABC were 
detectable over 14 days following treatment with nanoformulated MABC. The 
folate coating increased the blood levels of ABC by approximately 2.5-fold 
compared to non-coated formulations and up to 18-fold compared to native drug. 
Interestingly, no MABC was detected in the blood of mice treated with MABC 
nanoformulations. This suggests that following release from the nanoformulation, 
MABC was efficiently converted to ABC by blood and tissue esterases. Hence, 
folate coating of nanoformulated crystalline MABC could be an effective strategy 
to reduce HIV levels in its sanctuaries by maintaining sustained blood drug 
levels. 
4.5. CONCLUSIONS 
We demonstrate that a carboxylic acid ester prodrug of ABC has improved 
antiretroviral activities over the native hydrophilic compound. The improved 
lipophilicity facilitated the encasement of the prodrug into poloxamer 
nanoformulations with high drug loading. Notably, coating the prodrug with a 
folate-modified polymer directed to the folic acid receptor enhanced 
nanoformulation uptake, retention, and antiretroviral efficacy of the drug. MABC 
nanoformulations localized to recycling endosomal compartments in 
macrophages, as previously observed for nanoformulated atazanavir and 
ritonavir [32]. Of importance, following a single IM injection, blood concentrations 




4.6.1. MABC Synthesis 
 Modified ABC (MABC) was synthesized by esterification of myristic acid to 
the 5-hydroxyl- cyclopentene moiety of the drug. 
 MABC was recovered with 66% efficiency after purification. 
 When compared to ABC, the antiretroviral activity of MABC, was 
increased 2–fold in MDM. 
4.6.2. Synthesis of MABC Encased Nanoformulations 
 MABC was readily incorporated into P407 (NMABC) nanoparticles with a 
size range of 150-200 nm and a monodispersed cylindrical morphology.  
 The nanoformulations were stable at 4 °C and 25 °C for at least 8 weeks. 
4.6.3. PK Evaluation of MABC Nanoformulations  
 Folate-targeting of the nanoformulation facilitated human MDM uptake and 
retention, and improved antiretroviral efficacy when compared to NMABC 
and free MABC. 
 Macrophage drug depots were localized in recycling endosomes (Rab11 
and Rab14).  
 Following a single IM injection of NMABC or FA-NMABC in mice, blood 
concentrations of ABC were maintained over 14 days. 
 FA-NMABC enhanced blood drug levels in mice by 1.7-fold compared to 






Figure 4.1.  Synthesis of MABC. MABC was synthesized as illustrated at a final 
yield of 66%. The synthesis of MABC was accomplished through derivatization of 
the native compound with a cleavable fatty acid ester in four steps; (1) The 
hydroxyl and amino groups of ABC were protected using TBSCl, and DMTr-Cl 
respectively, (2, 3) the TBSCl groupd was selectively removed, followed by 
selective coupling of myristoyl chloride at 5-OH position of ABC, finally,  (4) the 
DMTr-Cl protecting group was removed using TFA to yield final product. MABC 




Figure 4.2. Characterization of MABC. Covalent linkage of myristic acid to the 
5’-O-hydroxyl group of ABC was confirmed by nuclear agnetic resonance, 
Fourier transform infrared spectroscopy and tandem mass spectrometry (1H-
NMR, FTIR and MS/MS); (A) The 1H-NMR spectrum of MABC showed the 
presence of an intense broad peak at 1.21-1.50 ppm. This peak corresponds to 
the aliphatic protons on the fatty acid moiety. (B) Peaks at 2915 cm-1 and 2850 
cm-1 in MABC FTIR spectrum correspond to alkane (CH2-CH2) stretching of the 




Figure 4.3. Antiviral activity of ABC and MABC in HIV-1ADA infected MDM. 
MDM were treated with various concentrations of ABC or MABC for 60 min and 
then challenged with HIV-1ADA at a multiplicity of infection of 0.01 infectious viral 
particles/cell for 4 h. The cells were incubated for a further 10 days with MCSF-
free media containing the same drug concentration. HIV RT activity was 







Figure 4.4. Morphology and stability of NMABC. SEM images of (A) NMABC 
and (B) FA-NMABC nanoformulations. Both formulations appeared as cylindrical 
monodispersed particles of ~200 nm. Stability of the NMABC nanoformulation 








Figure 4.5.Characterization of nanoformulated MABC using 1H-NMR 
spectroscopy.   The 1H-NMR spectrum of NMABC showed the presence of a 
singlet at 3.7 ppm that corresponds to the methylene-repeating unit of the 
polymer. Peaks corresponding to the myristoylated prodrug protons are also 






Figure 4.6. MDM uptake and retention of NMABC and FA-NMABC. (A) MDM 
uptake of 100 µM NMABC or FA-NMABC was determined over 8 h. For uptake 
studies, 50 µM free folic acid (FA) was added to MDM prior to treatment with FA-
NMABC to block FOLR binding. (B) MDM retention of NMABC or FA-NMABC 
was determined over 15 days. For uptake studies, statistical differences were 
determined using one-way ANOVA among three groups; for retention studies 







Figure 4.7. Antiretroviral activity of NMABC and FA-NMABC measured in 
MDM. Antiretroviral activity was determined in MDM treated for 8 h with 100 µM 
free MABC or nanoformulated MABC and then infected with HIV-1ADA at 1, 5, 10 
or 15 days following drug loading. HIV replication was determined 10 days after 




Figure 4.8. Subcellular localization of nanoformulated MABC in MDM. MDM 
cultured in 8 well Lab-Tek II CC2 chamber slides were treated with 100 μM 
CF633-labeled FA-NMABC or CF633-labeled NMABC for 8 h then fixed and 
stained with antibodies to Rab7, -11, -14, and LAMP1 as described [20]. (A) Co-
localization is observed as a yellow punctate pattern throughout the cytoplasm 
and perinuclear cell regions in merged images of red nanoparticles and green 
subcellular compartments. (B) Percent fluorescence overlap was quantitated 
using ImageJ software, and JACoP plug-in. Statistical differences were 






Figure 4.9. Plasma and tissue drug levels of nanoformulated MABC in mice. 
Balb/c mice were administered intramuscularly 50 mg /kg equivalents of ABC 
using free ABC, NMABC or FA-NMABC on day 0 and sacrificed on day 14. 
Whole blood was collected into acetonitrile for drug analysis on days 1, 3, 5, 7, 9, 
12, and 14 after treatment. ABC levels were determined by UPLC-MS/MS. Data 
are expressed as mean ± standard error of mean. *** (P < 0.0001), *(P < 0.05) 
statistically different from ABC as determined by 2-way ANOVA and Bonferroni’s 
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Even though the prodrugs synthesis, followed by its encapsulation into 
long acting PLGA and pluronic nanoformulations showed considerable 
improvement over poor efficacy and PK/PD profile of native drug, pitfall exists. 
Firstly, the manufacturing scheme was not optimized to clinical translation; 
moreover it was design for proof of concept studies. There is further need to 
generate more robust manufacturing process that generates particles with 
homogeneous physicochemical parameters. For instance, in current methods, 
purification of nanoformulation using centrifugation led to particles aggregation 
that poses a major challenge in resuspending the particles with initial size and 
size distribution. Secondly, robust lyophilization methods need to develop, if we 
chose to develop powder formulation for longer stability.  
Therefore, future work should employ other alternative purification 
techniques such as tangential flow filtration (TFF) to circumvent the aggregation 
problem associated with conventional centrifugation. TFF is an efficient method 
of purification using membrane filtration to isolate nanoparticle and free 
polymers, and/or unencapsulated drugs.  
The scope of this research limited to develop two separate prodrugs; 
phosphorylated pro-drug to bypass inefficient monophosphorylation conversion, 
and myristoylated prodrugs to improve hydrophobicity that encourages its 
encapsulation in to long acting nanoformulations. The probabilities of developing 
phosphorylated prodrugs with fatty acid end chain that pose improve 
phosphorylation and hydrophobicity concomitantly should be tested in future.  
140 
 
We can improve the PK of our nanoformulated MABC using a range of 
particle surface ligands or through the use of mixed lineage kinase inhibitors that 
can affect autophagy and prolong the nanoparticle storage capacities. If 
successful, this would improve antiretroviral activities and facilitate MABC’s use 
as a component in a long-acting ART regimen. Such strategies are now being 
tested in relevant mouse models of HIV/AIDS. Parallel development of a 
nanoformulated hydrophobic prodrug of 3TC would provide a combination drug 
regimen with MABC and a long-acting formulation of the integrase inhibitor 
dolutegravir. Future development of a combination long acting prodrug-based 
delivery system would be a considerable benefit in the management of HIV 
infection. 
 
 
 
 
 
 
